0001047335 NATIONAL HEALTHCARE CORP false --12-31 Q3 2024 0.01 0.01 45,000,000 45,000,000 15,440,970 15,440,970 15,350,661 15,350,661 0.59 0.61 0.61 0.57 0.59 0.59 2 15 1,606,000 1 1,928 48 37,305,000 1,557,000 62 2 0 0 637,409 2 331,037 311,352 642,389 6.8 5 0.30 0.65 21 false false false false 0001047335 2024-01-01 2024-09-30 xbrli:shares 0001047335 2024-11-04 thunderdome:item iso4217:USD 0001047335 2024-07-01 2024-09-30 0001047335 2023-07-01 2023-09-30 0001047335 2023-01-01 2023-09-30 iso4217:USD xbrli:shares 0001047335 2024-09-30 0001047335 2023-12-31 0001047335 nhc:WhiteOakSeniorLivingMember 2024-01-01 2024-09-30 0001047335 nhc:WhiteOakSeniorLivingMember 2023-01-01 2023-09-30 0001047335 nhc:OtherBusinessAcquisitionsMember 2024-01-01 2024-09-30 0001047335 nhc:OtherBusinessAcquisitionsMember 2023-01-01 2023-09-30 0001047335 2022-12-31 0001047335 2023-09-30 0001047335 us-gaap:CommonStockMember 2023-12-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001047335 us-gaap:RetainedEarningsMember 2023-12-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001047335 us-gaap:NoncontrollingInterestMember 2023-12-31 0001047335 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001047335 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001047335 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001047335 2024-01-01 2024-03-31 0001047335 us-gaap:CommonStockMember 2024-03-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001047335 us-gaap:RetainedEarningsMember 2024-03-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001047335 us-gaap:NoncontrollingInterestMember 2024-03-31 0001047335 2024-03-31 0001047335 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001047335 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001047335 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001047335 2024-04-01 2024-06-30 0001047335 us-gaap:CommonStockMember 2024-06-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001047335 us-gaap:RetainedEarningsMember 2024-06-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001047335 us-gaap:NoncontrollingInterestMember 2024-06-30 0001047335 2024-06-30 0001047335 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001047335 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001047335 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001047335 us-gaap:CommonStockMember 2024-09-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001047335 us-gaap:RetainedEarningsMember 2024-09-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001047335 us-gaap:NoncontrollingInterestMember 2024-09-30 0001047335 us-gaap:CommonStockMember 2022-12-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001047335 us-gaap:RetainedEarningsMember 2022-12-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001047335 us-gaap:NoncontrollingInterestMember 2022-12-31 0001047335 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001047335 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001047335 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001047335 2023-01-01 2023-03-31 0001047335 us-gaap:CommonStockMember 2023-03-31 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001047335 us-gaap:RetainedEarningsMember 2023-03-31 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001047335 us-gaap:NoncontrollingInterestMember 2023-03-31 0001047335 2023-03-31 0001047335 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001047335 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001047335 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001047335 2023-04-01 2023-06-30 0001047335 us-gaap:CommonStockMember 2023-06-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001047335 us-gaap:RetainedEarningsMember 2023-06-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001047335 us-gaap:NoncontrollingInterestMember 2023-06-30 0001047335 2023-06-30 0001047335 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001047335 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001047335 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001047335 us-gaap:CommonStockMember 2023-09-30 0001047335 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001047335 us-gaap:RetainedEarningsMember 2023-09-30 0001047335 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001047335 us-gaap:NoncontrollingInterestMember 2023-09-30 xbrli:pure utr:Y 0001047335 srt:MinimumMember 2024-09-30 0001047335 srt:MaximumMember 2024-09-30 0001047335 us-gaap:BuildingAndBuildingImprovementsMember srt:MinimumMember 2024-09-30 0001047335 us-gaap:BuildingAndBuildingImprovementsMember srt:MaximumMember 2024-09-30 0001047335 nhc:EquipmentAndFurnitureMember srt:MinimumMember 2024-09-30 0001047335 nhc:EquipmentAndFurnitureMember srt:MaximumMember 2024-09-30 0001047335 nhc:RefundableAdvanceFeesMember 2024-01-01 2024-09-30 0001047335 nhc:OriginalEntryFeeMember 2024-01-01 2024-09-30 0001047335 nhc:AppreciationMember 2024-01-01 2024-09-30 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2024-08-01 2024-08-01 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2024-08-01 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember stpr:SC 2024-08-01 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2024-07-01 2024-09-30 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2024-01-01 2024-09-30 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2023-07-01 2023-09-30 0001047335 nhc:WhiteOakSeniorLivingPortfolioMember 2023-01-01 2023-09-30 0001047335 nhc:InpatientServicesMember 2024-07-01 2024-09-30 0001047335 nhc:InpatientServicesMember 2023-07-01 2023-09-30 0001047335 nhc:InpatientServicesMember 2024-01-01 2024-09-30 0001047335 nhc:InpatientServicesMember 2023-01-01 2023-09-30 0001047335 nhc:HomecareAndHospiceMember 2024-07-01 2024-09-30 0001047335 nhc:HomecareAndHospiceMember 2023-07-01 2023-09-30 0001047335 nhc:HomecareAndHospiceMember 2024-01-01 2024-09-30 0001047335 nhc:HomecareAndHospiceMember 2023-01-01 2023-09-30 0001047335 nhc:MedicareMember 2024-07-01 2024-09-30 0001047335 nhc:MedicareMember 2023-07-01 2023-09-30 0001047335 nhc:MedicareMember 2024-01-01 2024-09-30 0001047335 nhc:MedicareMember 2023-01-01 2023-09-30 0001047335 nhc:ManagedCareMember 2024-07-01 2024-09-30 0001047335 nhc:ManagedCareMember 2023-07-01 2023-09-30 0001047335 nhc:ManagedCareMember 2024-01-01 2024-09-30 0001047335 nhc:ManagedCareMember 2023-01-01 2023-09-30 0001047335 nhc:MedicaidMember 2024-07-01 2024-09-30 0001047335 nhc:MedicaidMember 2023-07-01 2023-09-30 0001047335 nhc:MedicaidMember 2024-01-01 2024-09-30 0001047335 nhc:MedicaidMember 2023-01-01 2023-09-30 0001047335 nhc:PrivatePayAndOtherMember 2024-07-01 2024-09-30 0001047335 nhc:PrivatePayAndOtherMember 2023-07-01 2023-09-30 0001047335 nhc:PrivatePayAndOtherMember 2024-01-01 2024-09-30 0001047335 nhc:PrivatePayAndOtherMember 2023-01-01 2023-09-30 0001047335 nhc:MedicaidMember 2024-07-01 2024-09-30 0001047335 nhc:MedicaidMember 2023-07-01 2023-09-30 0001047335 nhc:MedicaidMember 2024-01-01 2024-09-30 0001047335 nhc:MedicaidMember 2023-01-01 2023-09-30 0001047335 nhc:MedicareAndMedicaidMember 2024-09-30 0001047335 nhc:MedicareAndMedicaidMember 2023-12-31 0001047335 stpr:FL 2024-09-30 0001047335 nhc:NationalMember 2024-09-30 0001047335 nhc:NationalMember 2024-07-01 2024-09-30 0001047335 nhc:NationalMember 2023-07-01 2023-09-30 0001047335 nhc:NationalMember 2024-01-01 2024-09-30 0001047335 nhc:NationalMember 2023-01-01 2023-09-30 0001047335 nhc:WorkersCompensationRevenueMember 2024-07-01 2024-09-30 0001047335 nhc:WorkersCompensationRevenueMember 2023-07-01 2023-09-30 0001047335 nhc:WorkersCompensationRevenueMember 2024-01-01 2024-09-30 0001047335 nhc:WorkersCompensationRevenueMember 2023-01-01 2023-09-30 0001047335 us-gaap:ProfessionalLiabilityInsuranceMember 2024-07-01 2024-09-30 0001047335 us-gaap:ProfessionalLiabilityInsuranceMember 2023-07-01 2023-09-30 0001047335 us-gaap:ProfessionalLiabilityInsuranceMember 2024-01-01 2024-09-30 0001047335 us-gaap:ProfessionalLiabilityInsuranceMember 2023-01-01 2023-09-30 0001047335 nhc:HomecareAgencyInNashvilleTennesseeMember 2023-12-31 0001047335 2024-01-01 2024-01-31 0001047335 nhc:InpatientServicesSegmentMember 2024-07-01 2024-09-30 0001047335 nhc:HomecareServicesSegmentMember 2024-07-01 2024-09-30 0001047335 us-gaap:AllOtherSegmentsMember 2024-07-01 2024-09-30 0001047335 nhc:InpatientServicesSegmentMember 2023-07-01 2023-09-30 0001047335 nhc:HomecareServicesSegmentMember 2023-07-01 2023-09-30 0001047335 us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0001047335 nhc:InpatientServicesSegmentMember 2024-01-01 2024-09-30 0001047335 nhc:HomecareServicesSegmentMember 2024-01-01 2024-09-30 0001047335 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-09-30 0001047335 nhc:InpatientServicesSegmentMember 2023-01-01 2023-09-30 0001047335 nhc:HomecareServicesSegmentMember 2023-01-01 2023-09-30 0001047335 us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0001047335 nhc:TwoLeasesWithNHIMember 2024-09-30 0001047335 nhc:LeaseOneWithNhiMember 2024-09-30 0001047335 nhc:NHILeaseAgreementMember 2024-09-30 0001047335 nhc:BothNHILeaseAgreementsMember 2024-07-01 2024-09-30 0001047335 nhc:BothNHILeaseAgreementsMember 2023-07-01 2023-09-30 0001047335 nhc:BothNHILeaseAgreementsMember 2024-01-01 2024-09-30 0001047335 nhc:BothNHILeaseAgreementsMember 2023-01-01 2023-09-30 0001047335 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001047335 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001047335 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001047335 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001047335 us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001047335 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001047335 us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 nhc:NHICommonStockMember 2024-09-30 0001047335 nhc:NHICommonStockMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-09-30 0001047335 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001047335 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001047335 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001047335 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001047335 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001047335 nhc:InpatientServicesSegmentMember 2023-12-31 0001047335 nhc:HomecareAndHospiceSegmentMember 2023-12-31 0001047335 nhc:HomecareAndHospiceSegmentMember 2024-01-01 2024-09-30 0001047335 nhc:InpatientServicesSegmentMember 2024-09-30 0001047335 nhc:HomecareAndHospiceSegmentMember 2024-09-30 0001047335 us-gaap:TradeNamesMember 2024-09-30 0001047335 us-gaap:TradeNamesMember 2023-12-31 0001047335 nhc:CertificatesOfNeedMember 2024-09-30 0001047335 nhc:CertificatesOfNeedMember 2023-12-31 0001047335 us-gaap:LicensingAgreementsMember 2024-09-30 0001047335 us-gaap:LicensingAgreementsMember 2023-12-31 0001047335 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001047335 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001047335 nhc:SalariesWagesAndBenefitsMember 2024-07-01 2024-09-30 0001047335 nhc:SalariesWagesAndBenefitsMember 2023-07-01 2023-09-30 0001047335 nhc:SalariesWagesAndBenefitsMember 2024-01-01 2024-09-30 0001047335 nhc:SalariesWagesAndBenefitsMember 2023-01-01 2023-09-30 0001047335 2023-01-01 2023-12-31 0001047335 nhc:ExercisePriceRange1Member 2024-09-30 0001047335 nhc:ExercisePriceRange1Member 2024-01-01 2024-09-30 0001047335 nhc:ExercisePriceRange2Member 2024-09-30 0001047335 nhc:ExercisePriceRange2Member 2024-01-01 2024-09-30 0001047335 nhc:CreditFacilityMember 2024-09-30 0001047335 nhc:CreditFacilityMember 2024-08-01 0001047335 nhc:CreditFacilityMember 2024-08-01 2024-08-01 0001047335 nhc:TermFacilityMember nhc:CreditFacilityMember 2024-08-01 0001047335 us-gaap:RevolvingCreditFacilityMember nhc:CreditFacilityMember 2024-08-01 0001047335 nhc:CreditFacilityMember srt:MinimumMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-08-01 2024-08-01 0001047335 nhc:CreditFacilityMember srt:MaximumMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-08-01 2024-08-01 0001047335 nhc:CreditFacilityMember srt:MinimumMember us-gaap:BaseRateMember 2024-08-01 2024-08-01 0001047335 nhc:CreditFacilityMember srt:MaximumMember us-gaap:BaseRateMember 2024-08-01 2024-08-01

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission file number 001-13489
(Exact name of registrant as specified in its Charter)

Delaware | 52-2057472
(State or other jurisdiction of | (I.R.S. Employer
incorporation or organization | Identification No.)

100 E. Vine Street
Murfreesboro, TN 37130
(Address of principal executive offices)
(Zip Code)

(615) 890–2020
Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class | Trading Symbols(s) | Name of each exchange on which registered
Common, $0.01 par value | NHC | NYSE American

Indicate by check mark whether the registrant: (1) Has filed all reports required to be filed by Section 13 or 15(d), of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S–T (§ 232.405 of this chapter) during the preceding 12 months (or for such period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated filer ☒ | Accelerated filer ☐
Non–accelerated filer ☐ | Smaller reporting company ☐
| Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as is defined in Rule 12b–2 of the Exchange Act). Yes ☐ No ☒
15,441,070 shares of common stock of the registrant were outstanding as of November 4, 2024.

1

Table of Contents

Table of Contents

PART I. FINANCIAL INFORMATION
| Page
Item 1. | Financial Statements | 3
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 27
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 39
Item 4. | Controls and Procedures | 40
PART II. OTHER INFORMATION
Item 1. | Legal Proceedings | 40
Item 1A | Risk Factors | 40
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 40
Item 3. | Defaults Upon Senior Securities | 40
Item 4. | Mine Safety Disclosures | 40
Item 5. | Other Information | 40
Item 6. | Exhibits | 41

2

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 328,674 |  |  | $ | 277,005 |  |  | $ | 894,415 |  |  | $ | 804,617 |
Other revenues |  |  | 11,524 |  |  |  | 11,480 |  |  |  | 34,172 |  |  |  | 36,013 |
Government stimulus income |  |  | - |  |  |  | - |  |  |  | 9,445 |  |  |  | - |
Net operating revenues and grant income |  |  | 340,198 |  |  |  | 288,485 |  |  |  | 938,032 |  |  |  | 840,630 |
Cost and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 213,395 |  |  |  | 182,664 |  |  |  | 576,609 |  |  |  | 525,782 |
Other operating |  |  | 82,509 |  |  |  | 72,490 |  |  |  | 238,092 |  |  |  | 217,213 |
Facility rent |  |  | 10,886 |  |  |  | 10,094 |  |  |  | 31,804 |  |  |  | 30,087 |
Depreciation and amortization |  |  | 10,619 |  |  |  | 10,135 |  |  |  | 30,543 |  |  |  | 30,266 |
Interest |  |  | 1,742 |  |  |  | 77 |  |  |  | 1,788 |  |  |  | 268 |
Total costs and expenses |  |  | 319,151 |  |  |  | 275,460 |  |  |  | 878,836 |  |  |  | 803,616 |
Income from operations |  |  | 21,047 |  |  |  | 13,025 |  |  |  | 59,196 |  |  |  | 37,014 |
Other income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non–operating income |  |  | 4,224 |  |  |  | 4,097 |  |  |  | 14,865 |  |  |  | 12,116 |
Unrealized gains/(losses) on marketable equity securities |  |  | 32,767 |  |  |  | (3,093 | ) |  |  | 56,290 |  |  |  | 2,943 |
Income before income taxes |  |  | 58,038 |  |  |  | 14,029 |  |  |  | 130,351 |  |  |  | 52,073 |
Income tax provision |  |  | (15,338 | ) |  |  | (3,908 | ) |  |  | (34,294 | ) |  |  | (14,750 | )
Net income |  |  | 42,700 |  |  |  | 10,121 |  |  |  | 96,057 |  |  |  | 37,323 |
Net (income)/loss attributable to noncontrolling interest |  |  | 89 |  |  |  | 267 |  |  |  | (211 | ) |  |  | 1,069 |
Net income attributable to National HealthCare Corporation |  | $ | 42,789 |  |  | $ | 10,388 |  |  | $ | 95,846 |  |  | $ | 38,392 |
Earnings per share attributable to National HealthCare Corporation stockholders: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 2.78 |  |  | $ | 0.68 |  |  | $ | 6.23 |  |  | $ | 2.51 |
Diluted |  | $ | 2.73 |  |  | $ | 0.68 |  |  | $ | 6.15 |  |  | $ | 2.50 |
Weighted average common shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 15,411,680 |  |  |  | 15,299,913 |  |  |  | 15,384,758 |  |  |  | 15,311,453 |
Diluted |  |  | 15,667,321 |  |  |  | 15,324,511 |  |  |  | 15,576,294 |  |  |  | 15,334,269 |
Dividends declared per common share |  | $ | 0.61 |  |  | $ | 0.59 |  |  | $ | 1.81 |  |  | $ | 1.75 |

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

3

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Statements of Comprehensive Income

(unaudited – in thousands)

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net income |  | $ | 42,700 |  |  | $ | 10,121 |  |  | $ | 96,057 |  |  | $ | 37,323 |
Other comprehensive income/(loss): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unrealized gains/(losses) on investments in marketable debt securities |  |  | 3,516 |  |  |  | (1,185 | ) |  |  | 3,074 |  |  |  | (605 | )
Reclassification adjustment for realized losses on sales of marketable debt securities |  |  | - |  |  |  | - |  |  |  | 1,388 |  |  |  | 20 |
Income tax (expense)/benefit related to items of other comprehensive income |  |  | (460 | ) |  |  | 124 |  |  |  | (711 | ) |  |  | 3 |
Other comprehensive income/(loss), net of tax |  |  | 3,056 |  |  |  | (1,061 | ) |  |  | 3,751 |  |  |  | (582 | )
Net (income)/loss attributable to noncontrolling interest |  |  | 89 |  |  |  | 267 |  |  |  | (211 | ) |  |  | 1,069 |
Comprehensive income attributable to National HealthCare Corporation |  | $ | 45,845 |  |  | $ | 9,327 |  |  | $ | 99,597 |  |  | $ | 37,810 |

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

4

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Balance Sheets

(in thousands)

|  | September 30, 2024 |  |  | December 31, 2023 |
|  | unaudited |  |  |  |  |
Assets |  |  |  |  |  |  |  |
Current Assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 84,807 |  |  | $ | 107,076 |
Restricted cash and cash equivalents, current portion |  |  | 29,032 |  |  |  | 17,725 |
Marketable equity securities |  |  | 164,754 |  |  |  | 111,117 |
Marketable debt securities |  |  | - |  |  |  | 5,427 |
Restricted marketable equity securities |  |  | 23,001 |  |  |  | 26,779 |
Restricted marketable debt securities, current portion |  |  | 2,045 |  |  |  | 12,822 |
Accounts receivable |  |  | 128,782 |  |  |  | 108,545 |
Inventories |  |  | 7,840 |  |  |  | 7,386 |
Prepaid expenses and other assets |  |  | 4,887 |  |  |  | 8,855 |
Notes receivable |  |  | 578 |  |  |  | 503 |
Total current assets |  |  | 445,726 |  |  |  | 406,235 |
Property and Equipment: |  |  |  |  |  |  |  |
Property and equipment, at cost |  |  | 1,283,184 |  |  |  | 1,101,681 |
Accumulated depreciation and amortization |  |  | (596,759 | ) |  |  | (608,352 | )
Net property and equipment |  |  | 686,425 |  |  |  | 493,329 |
Other Assets: |  |  |  |  |  |  |  |
Restricted cash and cash equivalents, less current portion |  |  | 1,235 |  |  |  | 1,167 |
Restricted marketable debt securities, less current portion |  |  | 121,866 |  |  |  | 109,478 |
Deposits and other assets |  |  | 10,084 |  |  |  | 14,786 |
Operating lease right-of-use assets |  |  | 85,926 |  |  |  | 94,201 |
Goodwill |  |  | 169,690 |  |  |  | 168,295 |
Intangible assets |  |  | 19,805 |  |  |  | 7,038 |
Investments in unconsolidated companies |  |  | 21,950 |  |  |  | 16,267 |
Total other assets |  |  | 430,556 |  |  |  | 411,232 |
Total assets |  | $ | 1,562,707 |  |  | $ | 1,310,796 |

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

5

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Balance Sheets (continued)

(in thousands, except share and per share amounts)

|  | September 30, 2024 |  |  | December 31, 2023 |
|  | unaudited |  |  |  |  |
Liabilities and Stockholders’ Equity |  |  |  |  |  |  |  |
Current Liabilities: |  |  |  |  |  |  |  |
Trade accounts payable |  | $ | 22,724 |  |  | $ | 19,194 |
Finance lease obligations, current portion |  |  | - |  |  |  | 860 |
Operating lease liabilities, current portion |  |  | 31,366 |  |  |  | 29,352 |
Accrued payroll |  |  | 89,757 |  |  |  | 84,110 |
Amounts due to third party payors |  |  | 18,815 |  |  |  | 18,369 |
Accrued risk reserves, current portion |  |  | 31,076 |  |  |  | 30,549 |
Other current liabilities |  |  | 37,289 |  |  |  | 22,991 |
Dividends payable |  |  | 9,419 |  |  |  | 9,051 |
Long-term debt due within one year |  |  | 7,500 |  |  |  | - |
Total current liabilities |  |  | 247,946 |  |  |  | 214,476 |
Long-term debt |  |  | 139,500 |  |  |  | - |
Operating lease liabilities, less current portion |  |  | 53,079 |  |  |  | 63,175 |
Accrued risk reserves, less current portion |  |  | 79,128 |  |  |  | 72,710 |
Refundable entrance fees |  |  | 6,063 |  |  |  | 6,376 |
Deferred income taxes |  |  | 30,842 |  |  |  | 17,200 |
Other noncurrent liabilities |  |  | 19,353 |  |  |  | 26,379 |
Total liabilities |  |  | 575,911 |  |  |  | 400,316 |
Equity: |  |  |  |  |  |  |  |
Common stock, $.01 par value; 45,000,000 shares authorized; 15,440,970 and 15,350,661 shares, respectively, issued and outstanding |  |  | 154 |  |  |  | 153 |
Capital in excess of par value |  |  | 230,635 |  |  |  | 227,604 |
Retained earnings |  |  | 755,532 |  |  |  | 687,599 |
Accumulated other comprehensive loss |  |  | (2,853 | ) |  |  | (6,604 | )
Total National HealthCare Corporation stockholders’ equity |  |  | 983,468 |  |  |  | 908,752 |
Noncontrolling interest |  |  | 3,328 |  |  |  | 1,728 |
Total equity |  |  | 986,796 |  |  |  | 910,480 |
Total liabilities and equity |  | $ | 1,562,707 |  |  | $ | 1,310,796 |

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

6

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Statements of Cash Flows

(unaudited – in thousands)

|  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |
Cash Flows From Operating Activities: |  |  |  |  |  |  |  |
Net income |  | $ | 96,057 |  |  | $ | 37,323 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 30,543 |  |  |  | 30,266 |
Equity in earnings of unconsolidated investments |  |  | (589 | ) |  |  | (1,941 | )
Distributions from unconsolidated investments |  |  | 512 |  |  |  | 470 |
Unrealized gains on marketable equity securities |  |  | (56,290 | ) |  |  | (2,943 | )
Realized (gains)/losses on sale of marketable securities |  |  | (331 | ) |  |  | 603 |
Gain on sale of unconsolidated company |  |  | (1,024 | ) |  |  | - |
Deferred income taxes |  |  | 15,559 |  |  |  | (1,059 | )
Stock–based compensation |  |  | 3,062 |  |  |  | 2,119 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | (19,898 | ) |  |  | (2,617 | )
Inventories |  |  | 598 |  |  |  | (285 | )
Prepaid expenses and other assets |  |  | 8,809 |  |  |  | 2,444 |
Operating lease obligations |  |  | 193 |  |  |  | (936 | )
Trade accounts payable |  |  | 3,530 |  |  |  | (487 | )
Accrued payroll |  |  | 1,989 |  |  |  | (2,791 | )
Amounts due to third party payors |  |  | 446 |  |  |  | (1,043 | )
Accrued risk reserves |  |  | 6,945 |  |  |  | 5,656 |
Other current liabilities |  |  | 12,434 |  |  |  | 14,035 |
Other noncurrent liabilities |  |  | (8,031 | ) |  |  | 6,669 |
Net cash provided by operating activities |  |  | 94,514 |  |  |  | 85,483 |
Cash Flows From Investing Activities: |  |  |  |  |  |  |  |
Purchases of property and equipment |  |  | (19,444 | ) |  |  | (19,300 | )
Acquisition of White Oak Senior Living, net of cash acquired |  |  | (215,896 | ) |  |  | - |
Acquisition of other businesses, net of cash acquired |  |  | 2,097 |  |  |  | (2,700 | )
Proceeds from the sale of unconsolidated company |  |  | 2,100 |  |  |  | - |
Investments in notes receivable |  |  | (75 | ) |  |  | (197 | )
Investments in unconsolidated companies |  |  | (8,370 | ) |  |  | - |
Purchases of marketable securities |  |  | (24,736 | ) |  |  | (21,763 | )
Proceeds from sale of marketable securities |  |  | 39,776 |  |  |  | 36,578 |
Net cash used in investing activities |  |  | (225,048 | ) |  |  | (7,382 | )
Cash Flows From Financing Activities: |  |  |  |  |  |  |  |
Borrowings under credit facility |  |  | 150,000 |  |  |  | - |
Repayments under credit facility |  |  | (3,000 | ) |  |  | - |
Principal payments under finance lease obligations |  |  | (860 | ) |  |  | (3,711 | )
Dividends paid to common stockholders |  |  | (27,545 | ) |  |  | (26,520 | )
Noncontrolling interest contributions |  |  | 1,389 |  |  |  | - |
Issuance of common shares |  |  | 13,471 |  |  |  | 260 |
Repurchase of common shares |  |  | (13,502 | ) |  |  | (2,482 | )
Entrance fee refunds |  |  | (313 | ) |  |  | (258 | )
Net cash provided by/(used in) financing activities |  |  | 119,640 |  |  |  | (32,711 | )
Net Increase/(Decrease) in Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents |  |  | (10,894 | ) |  |  | 45,390 |
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning of Period |  |  | 125,968 |  |  |  | 74,865 |
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, End of Period |  | $ | 115,074 |  |  | $ | 120,255 |
Balance Sheet Classifications: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 84,807 |  |  | $ | 100,308 |
Restricted cash and cash equivalents |  |  | 30,267 |  |  |  | 19,947 |
Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents |  | $ | 115,074 |  |  | $ | 120,255 |

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

7

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share and per share amounts)

(unaudited)

For the nine months ended September 30, 2024:

|  | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital in Excess of Par Value |  |  | Retained Earnings |  |  | Accumulated Other Comprehensive Loss |  |  | Non- controlling Interest |  |  | Total Stockholders' Equity |
Balance at January 1, 2024 |  |  | 15,350,661 |  |  | $ | 153 |  |  | $ | 227,604 |  |  | $ | 687,599 |  |  | $ | (6,604 | ) |  | $ | 1,728 |  |  | $ | 910,480 |
Net income |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 26,213 |  |  |  | – |  |  |  | 38 |  |  |  | 26,251 |
Other comprehensive loss |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (437 | ) |  |  | – |  |  |  | (437 | )
Stock–based compensation |  |  | – |  |  |  | – |  |  |  | 793 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 793 |
Shares sold – options exercised |  |  | 150,194 |  |  |  | 1 |  |  |  | 8,412 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 8,413 |
Repurchase of common shares |  |  | (101,131 | ) |  |  | – |  |  |  | (9,900 | ) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (9,900 | )
Dividends declared to common stockholders ($0.59 per share) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (9,086 | ) |  |  | – |  |  |  | – |  |  |  | (9,086 | )
Balance at March 31, 2024 |  |  | 15,399,724 |  |  | $ | 154 |  |  | $ | 226,909 |  |  | $ | 704,726 |  |  | $ | (7,041 | ) |  | $ | 1,766 |  |  |  | 926,514 |
Net income |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 26,844 |  |  |  | – |  |  |  | 262 |  |  |  | 27,106 |
Other comprehensive income |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 1,132 |  |  |  | – |  |  |  | 1,132 |
Stock–based compensation |  |  | – |  |  |  | – |  |  |  | 1,176 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 1,176 |
Shares sold – options exercised |  |  | 38,849 |  |  |  | – |  |  |  | 2,827 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 2,827 |
Repurchase of common shares |  |  | (15,636 | ) |  |  | – |  |  |  | (1,502 | ) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (1,502 | )
Dividends declared to common stockholders ($0.61 per share) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (9,408 | ) |  |  | – |  |  |  | – |  |  |  | (9,408 | )
Balance at June 30, 2024 |  |  | 15,422,937 |  |  |  | 154 |  |  |  | 229,410 |  |  |  | 722,162 |  |  |  | (5,909 | ) |  |  | 2,028 |  |  |  | 947,845 |
Net income/(loss) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 42,789 |  |  |  | – |  |  |  | (89 | ) |  |  | 42,700 |
Contributions attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,389 |  |  |  | 1,389 |
Other comprehensive income |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 3,056 |  |  |  | – |  |  |  | 3,056 |
Stock–based compensation |  |  | – |  |  |  | – |  |  |  | 1,093 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 1,093 |
Shares sold – options exercised |  |  | 34,417 |  |  |  |  |  |  |  | 2,232 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 2,232 |
Repurchase of common shares |  |  | (16,384 | ) |  |  | – |  |  |  | (2,100 | ) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (2,100 | )
Dividends declared to common stockholders ($0.61 per share) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (9,419 | ) |  |  | – |  |  |  | – |  |  |  | (9,419 | )
Balance at September 30, 2024 |  |  | 15,440,970 |  |  | $ | 154 |  |  | $ | 230,635 |  |  | $ | 755,532 |  |  | $ | (2,853 | ) |  | $ | 3,328 |  |  |  | 986,796 |

8

Table of Contents

For the nine months ended September 30, 2023:

|  | Common Stock |  |  | Capital in Excess of |  |  | Retained |  |  | Accumulated Other Comprehensive |  |  | Non- controlling |  |  | Total Stockholders’ |
|  | Shares |  |  | Amount |  |  | Par Value |  |  | Earnings |  |  | Loss |  |  | Interest |  |  | Equity |
Balance at January 1, 2023 |  |  | 15,357,746 |  |  | $ | 153 |  |  | $ | 226,991 |  |  | $ | 656,664 |  |  | $ | (9,532 | ) |  | $ | 3,238 |  |  | $ | 877,514 |
Net income/(loss) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 11,723 |  |  |  | – |  |  |  | (438 | ) |  |  | 11,285 |
Other comprehensive income |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 1,679 |  |  |  | – |  |  |  | 1,679 |
Stock–based compensation |  |  | – |  |  |  | – |  |  |  | 639 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 639 |
Shares sold – options exercised |  |  | 7,046 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |
Repurchase of common shares |  |  | (44,349 | ) |  |  | – |  |  |  | (2,482 | ) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (2,482 | )
Dividends declared to common stockholders ($0.57 per share) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (8,733 | ) |  |  | – |  |  |  | – |  |  |  | (8,733 | )
Balance at March 31, 2023 |  |  | 15,320,443 |  |  | $ | 153 |  |  | $ | 225,148 |  |  | $ | 659,654 |  |  | $ | (7,853 | ) |  | $ | 2,800 |  |  |  | 879,902 |
Net income/(loss) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 16,281 |  |  |  | – |  |  |  | (364 | ) |  |  | 15,917 |
Other comprehensive loss |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (1,200 | ) |  |  | – |  |  |  | (1,200 | )
Stock–based compensation |  |  | – |  |  |  | – |  |  |  | 772 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 772 |
Shares sold – options exercised |  |  | 100 |  |  |  | – |  |  |  | 6 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 6 |
Dividends declared to common stockholders ($0.59 per share) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (9,039 | ) |  |  | – |  |  |  | – |  |  |  | (9,039 | )
Balance at June 30, 2023 |  |  | 15,320,543 |  |  |  | 153 |  |  |  | 225,926 |  |  |  | 666,896 |  |  |  | (9,053 | ) |  |  | 2,436 |  |  |  | 886,358 |
Net income/(loss) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 10,388 |  |  |  | – |  |  |  | (267 | ) |  |  | 10,121 |
Other comprehensive loss |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (1,061 | ) |  |  | – |  |  |  | (1,061 | )
Stock–based compensation |  |  | – |  |  |  | – |  |  |  | 708 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 708 |
Shares sold – options exercised |  |  | 4,017 |  |  |  | – |  |  |  | 254 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 254 |
Dividends declared to common stockholders ($0.59 per share) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (9,040 | ) |  |  | – |  |  |  | – |  |  |  | (9,040 | )
Balance at September 30, 2023 |  |  | 15,324,560 |  |  |  | 153 |  |  |  | 226,888 |  |  |  | 668,244 |  |  |  | (10,114 | ) |  |  | 2,169 |  |  |  | 887,340 |

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

9

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Notes to Interim Condensed Consolidated Financial Statements

September 30, 2024

(unaudited)

Note 1 – Description of Business

National HealthCare Corporation (“NHC” or the “Company”) is a leading provider of senior health care services. As of September 30, 2024, we operate or manage, through certain affiliates, 80 skilled nursing facilities with a total of 10,349 licensed beds, 26 assisted living facilities with 1,413 units, nine independent living facilities, three behavioral health hospitals, 34 homecare agencies, and 32 hospice agencies. We operate specialized care units within certain of our healthcare centers such as Alzheimer's disease care units and sub-acute nursing units. In addition, we provide insurance services, management and accounting services, and we lease properties to operators of skilled nursing and assisted living facilities. We operate in 9 states and are located primarily in the southeastern United States.

Note 2 – Summary of Significant Accounting Policies

The listing below is not intended to be a comprehensive list of all our significant accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by U.S. generally accepted accounting principles (“GAAP”), with limited need for management’s judgment in their application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result. See our audited December 31, 2023 consolidated financial statements and notes thereto which contain accounting policies and other disclosures required by U.S. GAAP. Our audited December 31, 2023 consolidated financial statements are available at our web site: www.nhccare.com.

Basis of Presentation

The unaudited interim condensed consolidated financial statements to which these notes are attached include all normal, recurring adjustments which are necessary to fairly present the financial position, results of operations and cash flows of NHC. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by NHC. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to NHC and the noncontrolling interest in its consolidated statements of operations.

We assume that users of these interim financial statements have read or have access to the audited December 31, 2023 consolidated financial statements and that the adequacy of additional disclosure needed for a fair presentation, except in regard to material contingencies, may be determined in that context. Accordingly, footnotes and other disclosures which would substantially duplicate the disclosure contained in our most recent annual report to stockholders have been omitted. This interim financial information is not necessarily indicative of the results that may be expected for a full year for a variety of reasons.

Estimates and Assumptions

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and could cause our reported net income to vary significantly from period to period.

Net Patient Revenues and Accounts Receivable

Net patient revenues are derived from services rendered to patients for skilled and intermediate nursing, rehabilitation therapy, assisted living and independent living, home health care services, hospice services, and behavioral health services. Net patient revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient services. These amounts are due from patients, governmental programs, and other third-party payors, and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations.

10

Table of Contents

The Company recognizes revenue as its performance obligations are completed. Routine services are treated as a single performance obligation satisfied over time as services are rendered. These routine services represent a bundle of services that are not capable of being distinct. The performance obligations are satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time when those services are rendered. Contract liabilities are recorded for payments the Company receives in which performance obligations have not been completed.

The Company determines the transaction price based on established billing rates reduced by explicit price concessions provided to third party payors. Explicit price concessions are based on contractual agreements and historical experience. The Company considers the patient's ability and intent to pay the amount of consideration upon admission. Credit losses are recorded as bad debt expense, which is included as a component of other operating expenses in the interim condensed consolidated statements of operations. Bad debt expense was $2,574,000 and $7,098,000 for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, bad debt expense was $1,668,000 and $5,331,000, respectively. As of September 30, 2024 and December 31, 2023, the Company has recorded allowance for doubtful accounts of $10,859,000 and $8,054,000, respectively, as our best estimate of expected losses inherent in the accounts receivable balance.

Other Revenues

Other revenues include revenues from the provision of insurance services to other healthcare providers, management and accounting services to other healthcare providers, and rental income. Our insurance revenues consist of premiums that are generally paid in advance and then amortized into income over the policy period. We charge for management services based on a percentage of net revenues. We charge for accounting services based on a monthly fee or a fixed fee per bed of the healthcare center under contract. We record other revenues as the performance obligations are satisfied based on the terms of our contractual arrangements.

We recognize rental income based on the terms of our operating leases. Under certain of our leases, we receive variable rent, which is based on the increase in revenues of a lessee over a base year. We recognize variable rent annually or monthly, as applicable, when, based on the actual revenue of the lessee is earned.

Government Grants

We account for government grants in accordance with International Accounting Standards ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance, and as such, we recognize grant income on a systematic basis in line with the recognition of specific expenses and lost revenues for which the grants are intended to compensate.

For the nine months ended September 30, 2024, all conditions related to the Employee Retention Credit ("ERC") were met and the credit was recognized as government stimulus income. The ERC was established by the CARES Act and intended to help businesses retain their workforce and avoid layoffs during the pandemic. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. The qualified wages and health insurance benefits paid by the Company were related to the second, third and fourth quarters of 2020.

Segment Reporting

In accordance with the provisions of Accounting Standards Codification ("ASC") 280, Segment Reporting, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services. The Company also reports an “all other” category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. See Note 7 for further disclosure of the Company’s operating segments.

Other Operating Expenses

Other operating expenses include the costs of care and services that we provide to the residents of our facilities and the costs of maintaining our facilities. Our primary patient care costs include drugs, medical supplies, purchased professional services, food, and professional liability insurance and licensing fees. The primary facility costs include utilities and property insurance.

General and Administrative Costs

With the Company being a healthcare provider, the majority of our expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its corporate office costs, excluding stock-based compensation and incentive compensation, which were $6,288,000 and $19,678,000 for the three and nine months ended September 30, 2024, respectively. General and administrative costs were $5,661,000 and $16,309,000 for the three and nine months ended September 30, 2023, respectively. The increased general and administrative costs incurred during 2024 are due to acquisition-related expenses for the White Oak Senior Living portfolio. See Note 3 - Acquisition of White Oak Senior Living for additional detail regarding the acquisition.

11

Table of Contents

Long-Term Leases

The Company’s lease portfolio primarily consists of operating real estate leases for certain skilled nursing facilities, assisted and independent living facilities, homecare and hospice offices, regional offices, and pharmacy warehouses. The original terms of the leases typically range from two to fifteen years. Several of the real estate leases include renewal options which vary in length and may not include specific rent renewal amounts. We determine if an arrangement is a lease at inception of a contract. We determine the lease term by assuming exercise of renewal options that are reasonably certain.

The Company records right-of-use assets and liabilities for non-cancelable real estate operating leases with original or remaining lease terms in excess of one year. Leases with a lease term of 12 months or less at inception are not recorded and are expensed on a straight-line basis over the lease term. We recognize lease components and non-lease components together and not as separate parts of a lease for real estate leases.

Operating lease right-of-use assets and liabilities are recorded at the present value of the lease payments over the lease term. The present value of the lease payments are discounted using the incremental borrowing rate associated with each lease. The variable components of the lease payment that fluctuate with the operations of a health facility are not included in determining the right-of-use assets and lease liabilities. Rather, these variable components are expensed as incurred.

Property and Equipment

Property and equipment are recorded at cost or fair value, if acquired. Depreciation is provided by the straight-line method over the expected useful lives of the assets estimated as follows: buildings and improvements, 20-40 years and equipment and furniture, 3-15 years. Leasehold improvements are amortized over periods that do not exceed the non-cancelable respective lease terms using the straight-line method.

Business Combinations

We account for transactions that represent business combinations using the acquisition method of accounting in accordance with FASB ASC Topic 805, Business Combinations (Topic 805). Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts during the measurement period. The measurement period is defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date.

Goodwill generated from business combinations is recognized for the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. In determining the fair value of identifiable assets, we use various valuation techniques. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth, and discount rates

Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is subject to an annual impairment test. We perform our annual goodwill impairment assessment on the first day of the fourth quarter. Tests are performed more frequently if events occur, or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.

The Company’s indefinite-lived intangible assets consist of trade names and certificates of need and licenses. The Company reviews indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the fair value of the intangible asset is below its carrying amount.

Accrued Risk Reserves

We are self–insured for risks related to workers’ compensation and general and professional liability insurance. We have two wholly–owned limited purpose insurance companies that insure these risks. The accrued risk reserves include a liability for reported claims and estimates for incurred but unreported claims. Our policy is to engage an external, independent actuary to assist in estimating our exposure for claims obligations (for both asserted and unasserted claims). We reassess our accrued risk reserves on a quarterly basis.

Professional liability remains an area of particular concern to us. The long-term care industry has seen an increase in personal injury/wrongful death claims based on alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims could have a material adverse effect on our consolidated financial position, results of operations and cash flows. It is also possible that future events could cause us to make significant adjustments or revisions to these reserve estimates and cause our reported net income to vary significantly from period to period.

12

Table of Contents

We are principally self-insured for incidents occurring in all centers owned or leased by us. The coverage includes both primary policies and excess policies. In all years, settlements, if any, in excess of available insurance policy limits and our own reserves would be expensed by us.

Continuing Care Contracts

We have continuing care retirement centers (“CCRC”) within our operations. Residents at these retirement centers may enter into continuing care contracts with us. The contracts provide that 10% of the resident entry fee becomes non-refundable upon occupancy, and the remaining refundable portion of the entry fee is calculated using the lesser of the price at which the apartment is re-assigned or 90% of the original entry fee, plus 40% of any appreciation if the apartment value exceeds the original resident’s entry fee.

Non-refundable fees are included as a component of the transaction price and are amortized into revenue over the actuarily determined remaining life of the resident, which is the expected period of occupancy by the resident. We pay the refundable portion of our entry fees to residents when they relocate from our community and the apartment is re-occupied. Refundable entrance fees are not included as part of the transaction price and are classified as noncurrent liabilities in our consolidated balance sheets.

We also annually estimate the present value of the cost of future services and the use of facilities to be provided to the current CCRC residents and compare that amount with the balance of non-refundable deferred revenue from entrance fees received. If the present value of the cost of future services exceeds the related anticipated revenues, a liability is recorded with a corresponding charge to income. As of September 30, 2024, and December 31, 2023, we have recorded a future service obligation liability in the amount of $1,606,000. This obligation is reflected within other noncurrent liabilities in the interim condensed consolidated balance sheets.

Other Noncurrent Liabilities

Other noncurrent liabilities include reserves primarily related to various uncertain income tax positions, deferred revenue, and obligations to provide future services to our CCRC residents. Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation (“National”) and the non-refundable portion (10%) of CCRC entrance fees being amortized over the remaining life expectancies of the residents.

Noncontrolling Interest

The noncontrolling interest in a subsidiary is presented within total equity in the Company's interim condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its interim condensed consolidated statements of operations. The Company’s earnings per share is calculated based on net income attributable to NHC’s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of the subsidiary earnings, contributions, and distributions.

Variable Interest Entities

We have equity interests in unconsolidated limited liability companies that operate various post-acute and senior healthcare businesses. We analyze our investments in these limited liability companies to determine if the company is considered a variable interest entity (“VIE”) and would require consolidation. To the extent that we own interests in a VIE and we (i) have the power to direct the activities of the VIE and (ii) have the obligation or rights to absorb the VIE's losses or receive its benefits, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary.

The Company's maximum exposure to losses in its investments in unconsolidated VIEs cannot be quantified and may or may not be limited to its investment in the unconsolidated VIE. The investments in unconsolidated VIEs are classified as “investments in unconsolidated companies” in the interim condensed consolidated balance sheets.

Recently Issued Accounting Guidance

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvement to Reportable Segment Disclosures.” The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit and loss, and contain other disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2023, which will be the Company's fiscal year 2024, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact this standard will have on our disclosures.

13

Table of Contents

Note 3 – Acquisition of White Oak Senior Living

On August 1, 2024, the Company purchased certain assets and assumed certain liabilities of the White Oak Senior Living (“White Oak”) portfolio for a purchase price of $221,400,000. The White Oak portfolio consists of 22 healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities, four independent living facilities, and a long-term care pharmacy. The operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina (2,278 total beds/units). The acquisition represents both an expansion of NHC’s operations into a new state (North Carolina) and a strategic advancement of its growth in its existing operational footprint.

The Company utilized widely accepted income-based, market-based, and cost-based valuation approaches to perform the preliminary purchase price allocation.

The Company has performed a preliminary valuation analysis of the fair market value of White Oak’s assets acquired and liabilities assumed. The final valuation of the assets acquired and liabilities assumed was not complete as of September 30, 2024, but will be finalized within the allowable measurement period. The following table summarizes the allocation of the preliminary purchase price as of the transaction’s closing date (in thousands):

|  | Amount |
Cash and cash equivalents |  | $ | 9 |
Inventories |  |  | 1,054 |
Prepaid expenses and other assets |  |  | 137 |
Property and equipment |  |  | 203,695 |
Deferred tax asset |  |  | 2,499 |
Operating lease right-of-use assets |  |  | 11,380 |
Intangible assets |  |  | 12,765 |
Total assets acquired |  |  | 231,539 |
Operating lease liabilities, current portion |  |  | 424 |
Accrued payroll |  |  | 3,559 |
Other current liabilities |  |  | 1,085 |
Operating lease liabilities, less current portion |  |  | 10,956 |
Other noncurrent liabilities |  |  | 1,005 |
Total liabilities assumed |  |  | 17,029 |
Net identifiable assets acquired |  |  | 214,510 |
Goodwill |  |  | 1,395 |
Total estimated fair value of the acquisition |  | $ | 215,905 |

The indefinite-lived intangible assets acquired include the trade name of White Oak and the skilled nursing certificates of need and licenses. The goodwill is recorded in the inpatient services segment and is attributed to the workforce acquired and reputation of the business as part of the transaction. We expect the goodwill to be deductible for income tax purposes.

For the three and nine months ended September 30, 2024, White Oak contributed net operating revenues of $37,305,000 and income before income taxes of $1,557,000 that are included in the Company’s interim condensed consolidated statements of operations. The Company recognized $637,000 and $2,831,000 in acquisition-related expenses for the three and nine months ended September 30, 2024, respectively, in connection with the White Oak acquisition. These costs related to legal and other professional fees, which were included as a component of other operating expenses in the interim condensed consolidated statements of operations.

The following table contains unaudited pro forma interim condensed consolidated statements of operations information for the three months and nine months ended September 30, 2024 and 2023, assuming that the White Oak acquisition closed on January 1, 2023. The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed (in thousands).

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net operating revenues and grant income |  | $ | 358,334 |  |  | $ | 337,817 |  |  | $ | 1,065,418 |  |  | $ | 987,186 |
Income before income taxes |  |  | 58,881 |  |  |  | 14,087 |  |  |  | 134,777 |  |  |  | 49,113 |
Net income attributable to NHC |  | $ | 43,413 |  |  | $ | 10,431 |  |  | $ | 99,121 |  |  | $ | 34,064 |

14

Table of Contents

Note 4 – Net Patient Revenues

The Company disaggregates revenue from contracts with customers by service type and by payor.

Revenue by Service Type

The Company’s net patient services can generally be classified into the following two categories: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services (in thousands).

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net patient revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Inpatient services |  | $ | 293,026 |  |  | $ | 243,865 |  |  | $ | 790,664 |  |  | $ | 706,795 |
Homecare and hospice |  |  | 35,648 |  |  |  | 33,140 |  |  |  | 103,751 |  |  |  | 97,822 |
Total net patient revenue |  | $ | 328,674 |  |  | $ | 277,005 |  |  | $ | 894,415 |  |  | $ | 804,617 |

For inpatient and hospice services, revenue is recognized on a daily basis as each day represents a separate contract and performance obligation. For homecare, revenue is recognized when services are provided based on the number of days of service rendered in the period of care or on a per-visit basis. Typically, patients and third-party payors are billed monthly after services are performed or the patient is discharged, and payments are due based on contract terms.

As our performance obligations relate to contracts with a duration of one year or less, the Company is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients are typically under no obligation to remain admitted in our facilities or under our care. As the period between the time of service and time of payment is typically one year or less, the Company did not adjust for the effects of a significant financing component.

Revenue by Payor

Certain groups of patients receive funds to pay the cost of their care from a common source. The following table sets forth sources of net patient revenues for the periods indicated:

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
Source |  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Medicare |  |  | 30% |  |  |  | 33% |  |  |  | 32% |  |  |  | 35% |
Managed Care |  |  | 9% |  |  |  | 10% |  |  |  | 10% |  |  |  | 10% |
Medicaid |  |  | 33% |  |  |  | 32% |  |  |  | 30% |  |  |  | 30% |
Private Pay and Other |  |  | 28% |  |  |  | 25% |  |  |  | 28% |  |  |  | 25% |
Total |  |  | 100% |  |  |  | 100% |  |  |  | 100% |  |  |  | 100% |

Medicare covers skilled nursing services for beneficiaries who require nursing care and/or rehabilitation services following a hospitalization of at least three consecutive days. For each eligible day a Medicare beneficiary is in a skilled nursing facility, Medicare pays the facility a daily payment, subject to adjustment for certain factors such as a wage index in the geographic area. The payment covers all services provided by the skilled nursing facility for the beneficiary that day, including room and board, nursing, therapy and drugs, as well as an estimate of capital–related costs to deliver those services.

For homecare services, Medicare pays based on the acuity level of the patient and based on periods of care. A period of care is defined as a length of care up to 30 days with multiple continuous periods allowed. The services covered by the payment include all disciplines of care, in addition to medical supplies, within the scope of the home health benefit.

For hospice services, Medicare pays a daily rate to cover the hospice’s costs for providing services included in the patient care plan. Medicare makes daily payments based on 1 of 4 levels of hospice care. All hospice care and services offered to patients and their families must follow an individualized written plan of care that meets the patient’s needs.

15

Table of Contents

Our hospice service revenue is subject to certain limitations on payments from Medicare. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded. If applicable, we record these cap adjustments as a reduction to revenue.

Medicaid is operated by individual states with the financial participation of the federal government. The states in which we operate currently use prospective cost–based reimbursement systems. Under cost–based reimbursement systems, the skilled nursing facility is reimbursed for the reasonable direct and indirect allowable costs it incurred in a base year in providing routine resident care services as defined by the program.

Private pay, managed care, and other payment sources include commercial insurance, individual patient funds, managed care plans and the Veterans Administration. Private paying patients, private insurance carriers and the Veterans Administration generally pay based on the healthcare center's charges or specifically negotiated contracts. For private pay patients in skilled nursing, assisted living and independent living facilities, the Company bills for room and board charges, with the remittance being due on receipt of the statement and generally by the 10th day of the month the services are performed.

Certain managed care payors for homecare services pay on a per-visit basis. This revenue is recorded on an accrual basis based upon the date of services at amounts equal to its established or estimated per-visit rates.

State Relief Supplemental Funding

The Company received supplemental Medicaid payments from various states, including healthcare relief funding under the American Rescue Plan Act ("ARPA") and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses or various patient care related expenses. We have recorded $5,267,000 and $4,232,000 in net patient revenues for these supplemental Medicaid payments for the three months ended September 30, 2024 and 2023, respectively. We have recorded $11,314,000 and $15,362,000 in net patient revenues for these supplemental Medicaid payments for the nine months ended September 30, 2024 and 2023, respectively.

Third Party Payors

Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Noncompliance with such laws and regulations can be subject to regulatory actions including fines, penalties, and exclusion from the Medicare and Medicaid programs. We believe that we are following all applicable laws and regulations.

Medicare and Medicaid program revenues, as well as certain Managed Care program revenues, are subject to audit and retroactive adjustment by government representatives or their agents. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. We believe that any differences between the net revenues recorded, and final determination will not materially affect the consolidated financial statements. We have made provisions of approximately $18,815,000 and $18,369,000 as of September 30, 2024 and December 31, 2023, respectively, for various Medicare, Medicaid, and Managed Care claims reviews and current and prior year cost reports.

Note 5 – Other Revenues

Other revenues are outlined in the table below. Revenues from rental income include health care real estate properties owned by us and leased to third party operators. Revenues from management and accounting services include fees provided to manage and provide accounting services to other healthcare operators. Revenues from insurance services include premiums for workers’ compensation and professional liability insurance policies that our wholly owned insurance subsidiaries have written for certain healthcare operators to which we provide management or accounting services. "Other" revenues include miscellaneous health care related earnings (in thousands).

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Rental income |  | $ | 6,028 |  |  | $ | 5,958 |  |  | $ | 18,015 |  |  | $ | 17,966 |
Management and accounting services fees |  |  | 4,226 |  |  |  | 4,185 |  |  |  | 12,744 |  |  |  | 14,045 |
Insurance services |  |  | 818 |  |  |  | 989 |  |  |  | 2,506 |  |  |  | 2,920 |
Other |  |  | 452 |  |  |  | 348 |  |  |  | 907 |  |  |  | 1,082 |
Total other revenues |  | $ | 11,524 |  |  | $ | 11,480 |  |  | $ | 34,172 |  |  | $ | 36,013 |

16

Table of Contents

Rental Income

The Company leases real estate assets consisting of skilled nursing facilities and assisted living facilities to third party operators. Additionally, we sublease four Florida skilled nursing facilities included in our lease from National Health Investors (“NHI”) as noted in Note 8 – Long Term Leases.

Management Fees from National Health Corporation

We manage five skilled nursing facilities owned by National Health Corporation (“National”). We recognized management fees and interest on management fees from these facilities of $1,348,000 and $1,243,000 for the three months ended September 30, 2024 and 2023, respectively. We recognized management fees and interest on management fees of $4,014,000 and $3,968,000 from these facilities for the nine months ended September 30, 2024 and 2023, respectively.

Insurance Services

For workers’ compensation insurance services, the premium revenues reflected in the interim condensed consolidated statements of operations for the three months ended September 30, 2024 and 2023 were $529,000 and $678,000, respectively. The premium revenues reflected in the interim condensed consolidated statements of operations for the nine months ended September 30, 2024 and 2023 were $1,638,000 and $1,985,000, respectively. Associated losses and expenses including those for self-insurance are included in the interim condensed consolidated statements of operations as "Salaries, wages and benefits."

For professional liability insurance services, the premium revenues reflected in the interim condensed consolidated statements of operations for the three months ended September 30, 2024 and 2023 were $289,000 and $312,000, respectively. The premium revenues reflected in the interim condensed consolidated statements of operations for the nine months ended September 30, 2024 and 2023 were $868,000 and $935,000, respectively. Associated losses and expenses including those for self–insurance are included in the interim condensed consolidated statements of operations as "Other operating costs and expenses".

Note 6 – Non–Operating Income

Non–operating income is comprised of the following (in thousands):

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Dividends and net realized gains and losses on sales of securities |  | $ | 1,683 |  |  | $ | 1,690 |  |  | $ | 5,462 |  |  | $ | 4,604 |
Interest income |  |  | 2,603 |  |  |  | 2,222 |  |  |  | 7,790 |  |  |  | 5,571 |
Equity in earnings of unconsolidated investments |  |  | (62 | ) |  |  | 185 |  |  |  | 589 |  |  |  | 1,941 |
Gain on sale of unconsolidated company |  |  | - |  |  |  | - |  |  |  | 1,024 |  |  |  | - |
Total non-operating income |  | $ | 4,224 |  |  | $ | 4,097 |  |  | $ | 14,865 |  |  | $ | 12,116 |

Gain on sale of unconsolidated company

In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency located in Nashville, Tennessee. The total consideration paid to the Company was $2,100,000, which resulted in a gain of $1,024,000.

Note 7 – Business Segments

The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals; and (2) homecare and hospice services. These reportable operating segments are consistent with information used by the Company’s Chief Executive Officer, as chief operating decision maker (“CODM”), to assess performance and allocate resources. The Company also reports an “all other” category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office.

17

Table of Contents

The Company’s CODM evaluates performance and allocates capital resources to each segment based on an operating model that is designed to improve the quality of patient care and profitability of the Company while enhancing long-term shareholder value. The CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below.

The following table sets forth the Company’s unaudited interim condensed consolidated statements of operations by business segment (in thousands):

|  | Three Months Ended September 30, 2024 |
|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 293,026 |  |  | $ | 35,648 |  |  | $ | - |  |  | $ | 328,674 |
Other revenues |  |  | 370 |  |  |  | - |  |  |  | 11,154 |  |  |  | 11,524 |
Net operating revenues |  |  | 293,396 |  |  |  | 35,648 |  |  |  | 11,154 |  |  |  | 340,198 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 175,241 |  |  |  | 21,456 |  |  |  | 16,698 |  |  |  | 213,395 |
Other operating |  |  | 72,384 |  |  |  | 6,612 |  |  |  | 3,513 |  |  |  | 82,509 |
Rent |  |  | 8,422 |  |  |  | 602 |  |  |  | 1,862 |  |  |  | 10,886 |
Depreciation and amortization |  |  | 9,632 |  |  |  | 172 |  |  |  | 815 |  |  |  | 10,619 |
Interest |  |  | 1,742 |  |  |  | - |  |  |  | - |  |  |  | 1,742 |
Total costs and expenses |  |  | 267,421 |  |  |  | 28,842 |  |  |  | 22,888 |  |  |  | 319,151 |
Income/(loss) from operations |  |  | 25,975 |  |  |  | 6,806 |  |  |  | (11,734 | ) |  |  | 21,047 |
Non-operating income |  |  | - |  |  |  | - |  |  |  | 4,224 |  |  |  | 4,224 |
Unrealized gains on marketable equity securities |  |  | - |  |  |  | - |  |  |  | 32,767 |  |  |  | 32,767 |
Income before income taxes |  | $ | 25,975 |  |  | $ | 6,806 |  |  | $ | 25,257 |  |  | $ | 58,038 |

|  | Three Months Ended September 30, 2023 |
|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 243,865 |  |  | $ | 33,140 |  |  | $ | - |  |  | $ | 277,005 |
Other revenues |  |  | 297 |  |  |  | - |  |  |  | 11,183 |  |  |  | 11,480 |
Net operating revenues |  |  | 244,162 |  |  |  | 33,140 |  |  |  | 11,183 |  |  |  | 288,485 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 151,912 |  |  |  | 20,066 |  |  |  | 10,686 |  |  |  | 182,664 |
Other operating |  |  | 64,228 |  |  |  | 5,868 |  |  |  | 2,394 |  |  |  | 72,490 |
Rent |  |  | 8,186 |  |  |  | 538 |  |  |  | 1,370 |  |  |  | 10,094 |
Depreciation and amortization |  |  | 9,203 |  |  |  | 185 |  |  |  | 747 |  |  |  | 10,135 |
Interest |  |  | 77 |  |  |  | - |  |  |  | - |  |  |  | 77 |
Total costs and expenses |  |  | 233,606 |  |  |  | 26,657 |  |  |  | 15,197 |  |  |  | 275,460 |
Income/(loss) from operations |  |  | 10,556 |  |  |  | 6,483 |  |  |  | (4,014 | ) |  |  | 13,025 |
Non-operating income |  |  | - |  |  |  | - |  |  |  | 4,097 |  |  |  | 4,097 |
Unrealized losses on marketable equity securities |  |  | - |  |  |  | - |  |  |  | (3,093 | ) |  |  | (3,093 | )
Income/(loss) before income taxes |  | $ | 10,556 |  |  | $ | 6,483 |  |  | $ | (3,010 | ) |  | $ | 14,029 |

18

Table of Contents

|  | Nine Months Ended September 30, 2024 |
|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 790,664 |  |  | $ | 103,751 |  |  | $ | - |  |  | $ | 894,415 |
Other revenues |  |  | 710 |  |  |  | - |  |  |  | 33,462 |  |  |  | 34,172 |
Government stimulus income |  |  | - |  |  |  | - |  |  |  | 9,445 |  |  |  | 9,445 |
Net operating revenues and grant income |  |  | 791,374 |  |  |  | 103,751 |  |  |  | 42,907 |  |  |  | 938,032 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 474,190 |  |  |  | 63,761 |  |  |  | 38,658 |  |  |  | 576,609 |
Other operating |  |  | 207,883 |  |  |  | 18,977 |  |  |  | 11,232 |  |  |  | 238,092 |
Rent |  |  | 24,795 |  |  |  | 1,736 |  |  |  | 5,273 |  |  |  | 31,804 |
Depreciation and amortization |  |  | 27,646 |  |  |  | 545 |  |  |  | 2,352 |  |  |  | 30,543 |
Interest |  |  | 1,788 |  |  |  | - |  |  |  | - |  |  |  | 1,788 |
Total costs and expenses |  |  | 736,302 |  |  |  | 85,019 |  |  |  | 57,515 |  |  |  | 878,836 |
Income/(loss) from operations |  |  | 55,072 |  |  |  | 18,732 |  |  |  | (14,608 | ) |  |  | 59,196 |
Non-operating income |  |  | - |  |  |  | - |  |  |  | 14,865 |  |  |  | 14,865 |
Unrealized gains on marketable equity securities |  |  | - |  |  |  | - |  |  |  | 56,290 |  |  |  | 56,290 |
Income before income taxes |  | $ | 55,072 |  |  | $ | 18,732 |  |  | $ | 56,547 |  |  | $ | 130,351 |

|  | Nine Months Ended September 30, 2023 |
|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 706,795 |  |  | $ | 97,822 |  |  | $ | - |  |  | $ | 804,617 |
Other revenues |  |  | 894 |  |  |  | - |  |  |  | 35,119 |  |  |  | 36,013 |
Net operating revenues |  |  | 707,689 |  |  |  | 97,822 |  |  |  | 35,119 |  |  |  | 840,630 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 435,517 |  |  |  | 60,804 |  |  |  | 29,461 |  |  |  | 525,782 |
Other operating |  |  | 192,473 |  |  |  | 17,356 |  |  |  | 7,384 |  |  |  | 217,213 |
Rent |  |  | 24,520 |  |  |  | 1,639 |  |  |  | 3,928 |  |  |  | 30,087 |
Depreciation and amortization |  |  | 27,474 |  |  |  | 555 |  |  |  | 2,237 |  |  |  | 30,266 |
Interest |  |  | 268 |  |  |  | - |  |  |  | - |  |  |  | 268 |
Total costs and expenses |  |  | 680,252 |  |  |  | 80,354 |  |  |  | 43,010 |  |  |  | 803,616 |
Income/(loss) from operations |  |  | 27,437 |  |  |  | 17,468 |  |  |  | (7,891 | ) |  |  | 37,014 |
Non-operating income |  |  | - |  |  |  | - |  |  |  | 12,116 |  |  |  | 12,116 |
Unrealized gains on marketable equity securities |  |  | - |  |  |  | - |  |  |  | 2,943 |  |  |  | 2,943 |
Income before income taxes |  | $ | 27,437 |  |  | $ | 17,468 |  |  | $ | 7,168 |  |  | $ | 52,073 |

Note 8 – Long-Term Leases

Operating Leases

At September 30, 2024, we lease from NHI the real property of 28 skilled nursing facilities, five assisted living centers and three independent living centers under one lease agreement. As part of the lease agreement, we sublease four Florida skilled nursing facilities to a third-party operator. The lease includes base rent plus a percentage rent. The annual base rent is $32,625,000 in 2024, $32,225,000 in 2025, and $31,975,000 in 2026 with the lease term expiring in December 2026. The percentage rent is based on a quarterly calculation of revenue increases and is payable on a quarterly basis. Total facility rent expense to NHI was $10,085,000 and $9,300,000 for the three months ended September 30, 2024 and 2023, respectively. Total facility rent expense to NHI was $29,371,000 and $27,719,000 for the nine months ended September 30, 2024 and 2023, respectively.

19

Table of Contents

Minimum Lease Payments

The following table summarizes the maturity of our operating lease liabilities as of September 30, 2024 (in thousands):

|  | Operating Leases |
2025 |  | $ | 35,858 |
2026 |  |  | 35,183 |
2027 |  |  | 10,471 |
2028 |  |  | 1,702 |
2029 |  |  | 1,424 |
Thereafter |  |  | 11,768 |
Total minimum lease payments |  |  | 96,406 |
Less: amounts representing interest |  |  | (11,961 | )
Present value of future minimum lease payments |  |  | 84,445 |
Less: current portion |  |  | (31,366 | )
Noncurrent lease liabilities |  | $ | 53,079 |

20

Table of Contents

Note 9 – Earnings per Share

Basic net income per share is computed based on the weighted average number of common shares outstanding for each period presented. Diluted net income per share reflects the potential dilution that would have occurred if securities to issue common stock were exercised, converted, or resulted in the issuance of common stock that would have then shared in our earnings.

The following table summarizes the earnings and the weighted average number of common shares used in the calculation of basic and diluted earnings per share (in thousands, except for share and per share amounts):

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Basic: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares outstanding |  |  | 15,411,680 |  |  |  | 15,299,913 |  |  |  | 15,384,758 |  |  |  | 15,311,453 |
Net income attributable to National HealthCare Corporation |  | $ | 42,789 |  |  | $ | 10,388 |  |  | $ | 95,846 |  |  | $ | 38,392 |
Earnings per common share, basic |  | $ | 2.78 |  |  | $ | 0.68 |  |  | $ | 6.23 |  |  | $ | 2.51 |
Diluted: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares outstanding |  |  | 15,411,680 |  |  |  | 15,299,913 |  |  |  | 15,384,758 |  |  |  | 15,311,453 |
Effects of dilutive instruments |  |  | 255,641 |  |  |  | 24,598 |  |  |  | 191,536 |  |  |  | 22,816 |
Weighted average common shares outstanding |  |  | 15,667,321 |  |  |  | 15,324,511 |  |  |  | 15,576,294 |  |  |  | 15,334,269 |
Net income attributable to National HealthCare Corporation |  | $ | 42,789 |  |  | $ | 10,388 |  |  | $ | 95,846 |  |  | $ | 38,392 |
Earnings per common share, diluted |  | $ | 2.73 |  |  | $ | 0.68 |  |  | $ | 6.15 |  |  | $ | 2.50 |

For the three and nine months ending September 30, 2024, we did not exclude any stock options from the calculation of diluted weighted average shares of common stock outstanding. For the three and nine months ending September 30, 2023, 637,409 of stock options have been excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect.

Note 10 – Investments in Marketable Securities

Our investments in marketable equity securities are carried at fair value with the changes in unrealized gains and losses recognized in our results of operations at each measurement date. Our investments in marketable debt securities are classified as available for sale securities and carried at fair value with the unrealized gains and losses recognized through accumulated other comprehensive income at each measurement date. Any credit-related decline in fair market values below the amortized cost of our available for sale debt securities are recorded in our results of operations through an allowance for credit losses. Realized gains and losses from securities sales are recognized in results of operations upon disposition of the securities using the specific identification method on a trade date basis. Refer to Note 11 for a description of the Company's methodology for determining the fair value of marketable securities.

Marketable securities consist of the following (in thousands):

|  | September 30, 2024 |  |  | December 31, 2023 |
|  | Amortized Cost |  |  | Fair Value |  |  | Amortized Cost |  |  | Fair Value |
Investments available for sale: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable equity securities |  | $ | 30,176 |  |  | $ | 164,754 |  |  | $ | 30,176 |  |  | $ | 111,117 |
Corporate debt securities |  |  | – |  |  |  | – |  |  |  | 2,497 |  |  |  | 2,441 |
U.S. Treasury securities |  |  | – |  |  |  | – |  |  |  | 2,990 |  |  |  | 2,986 |
Restricted investments available for sale: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable equity securities |  |  | 17,702 |  |  |  | 23,001 |  |  |  | 24,134 |  |  |  | 26,779 |
Corporate debt securities |  |  | 59,267 |  |  |  | 58,812 |  |  |  | 59,586 |  |  |  | 57,731 |
Asset-based securities |  |  | 17,756 |  |  |  | 16,646 |  |  |  | 19,388 |  |  |  | 17,659 |
U.S. Treasury securities |  |  | 46,224 |  |  |  | 44,671 |  |  |  | 46,771 |  |  |  | 42,863 |
State and municipal securities |  |  | 3,813 |  |  |  | 3,782 |  |  |  | 4,106 |  |  |  | 4,047 |
|  | $ | 174,938 |  |  | $ | 311,666 |  |  | $ | 189,648 |  |  |  | 265,623 |

21

Table of Contents

Included in the marketable equity securities are the following (in thousands, except share amounts):

|  | September 30, 2024 |  |  | December 31, 2023 |
|  | Shares |  |  | Cost |  |  | Fair Value |  |  | Shares |  |  | Cost |  |  | Fair Value |
NHI Common Stock |  |  | 1,630,642 |  |  | $ | 24,734 |  |  | $ | 137,072 |  |  |  | 1,630,642 |  |  | $ | 24,734 |  |  | $ | 91,071 |

The amortized cost and estimated fair value of debt securities classified as available for sale, by contractual maturity, are as follows (in thousands):

|  | September 30, 2024 |  |  | December 31, 2023 |
|  | Cost |  |  | Fair Value |  |  | Cost |  |  | Fair Value |
Maturities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Within 1 year |  | $ | 24,509 |  |  | $ | 24,023 |  |  | $ | 19,664 |  |  | $ | 19,328 |
1 to 5 years |  |  | 71,047 |  |  |  | 69,082 |  |  |  | 81,517 |  |  |  | 77,118 |
6 to 10 years |  |  | 31,197 |  |  |  | 30,499 |  |  |  | 33,515 |  |  |  | 30,802 |
Over 10 years |  |  | 307 |  |  |  | 307 |  |  |  | 642 |  |  |  | 479 |
|  | $ | 127,060 |  |  | $ | 123,911 |  |  | $ | 135,338 |  |  | $ | 127,727 |

Gross unrealized gains related to marketable equity securities are $140,177,000 and $84,514,000 as of September 30, 2024 and December 31, 2023, respectively. Gross unrealized losses related to marketable equity securities are $300,000 and $928,000 as of September 30, 2024 and December 31, 2023, respectively. For the three months ended September 30, 2024 and 2023, the Company recognized net unrealized gains of $32,767,000 and net unrealized losses of $3,093,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations. For the nine months ended September 30, 2024 and 2023, the Company recognized net unrealized gains of $56,290,000 and 2,943,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations.

Gross unrealized gains related to available for sale marketable debt securities are $1,104,000 and $326,000 as of September 30, 2024 and December 31, 2023, respectively. Gross unrealized losses related to available for sale marketable debt securities are $4,253,000 and $7,937,000 as of September 30, 2024 and December 31, 2023, respectively.

The Company’s unrealized losses in our available for sale marketable debt securities were determined to be non-credit related. The Company has not recognized any credit related impairments for the nine months ended September 30, 2024 and 2023.

For the marketable debt securities in gross unrealized loss positions, (a) it is more likely than not that the Company will not be required to sell the investment securities before recovery of the unrealized losses, and (b) the Company expects that the contractual principal and interest will be received on the investment securities.

Proceeds from the sale of available for sale marketable securities during the nine months ended September 30, 2024 and 2023 were $39,776,000 and $36,578,000, respectively. Investment gains of $331,000 and investment losses of $603,000 were realized on these sales during the nine months ended September 30, 2024 and 2023, respectively.

Note 11 – Fair Value Measurements

The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This accounting standard establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs that may be used to measure fair value:

Level 1 – The valuation is based on quoted prices in active markets for identical instruments.

Level 2 – The valuation is based on observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model–based valuation techniques for which all significant assumptions are observable in the market.

Level 3 – The valuation is based on unobservable inputs that are supported by minimal or no market activity and that are significant to the fair value of the instrument. Level 3 valuations are typically performed using pricing models, discounted cash flow methodologies, or similar techniques that incorporate management’s own estimates of assumptions that market participants would use in pricing the instrument, or valuations that require significant management judgment or estimation.

22

Table of Contents

A financial instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.

The following table summarizes fair value measurements by level at September 30, 2024 and December 31, 2023 for assets and liabilities measured at fair value on a recurring basis (in thousands):

|  | Fair Value Measurements Using |
September 30, 2024 |  | Fair Value |  |  | Quoted Prices in Active Markets For Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Cash and cash equivalents |  | $ | 84,807 |  |  | $ | 84,807 |  |  | $ | – |  |  | $ | – |
Restricted cash and cash equivalents |  |  | 30,267 |  |  |  | 30,267 |  |  |  | – |  |  |  | – |
Marketable equity securities |  |  | 187,755 |  |  |  | 187,755 |  |  |  | – |  |  |  | – |
Corporate debt securities |  |  | 58,812 |  |  |  | 39,475 |  |  |  | 19,337 |  |  |  | – |
Asset–backed securities |  |  | 16,646 |  |  |  | – |  |  |  | 16,186 |  |  |  | 460 |
U.S. Treasury securities |  |  | 44,671 |  |  |  | 44,671 |  |  |  | – |  |  |  | – |
State and municipal securities |  |  | 3,782 |  |  |  | – |  |  |  | 3,782 |  |  |  | – |
Total financial assets |  | $ | 426,740 |  |  | $ | 386,975 |  |  | $ | 39,305 |  |  | $ | 460 |

|  | Fair Value Measurements Using |
December 31, 2023 |  | Fair Value |  |  | Quoted Prices in Active Markets For Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Cash and cash equivalents |  | $ | 107,076 |  |  | $ | 107,076 |  |  | $ | – |  |  | $ | – |
Restricted cash and cash equivalents |  |  | 18,892 |  |  |  | 18,892 |  |  |  | – |  |  |  | – |
Marketable equity securities |  |  | 137,896 |  |  |  | 137,896 |  |  |  | – |  |  |  | – |
Corporate debt securities |  |  | 60,171 |  |  |  | 42,860 |  |  |  | 17,311 |  |  |  | – |
Asset–backed securities |  |  | 17,659 |  |  |  | – |  |  |  | 17,210 |  |  |  | 449 |
U.S. Treasury securities |  |  | 45,850 |  |  |  | 45,850 |  |  |  | – |  |  |  | – |
State and municipal securities |  |  | 4,047 |  |  |  | – |  |  |  | 4,047 |  |  |  | – |
Total financial assets |  | $ | 391,591 |  |  | $ | 352,574 |  |  | $ | 38,568 |  |  | $ | 449 |

Note 12 – Goodwill and Other Intangible Assets

At September 30, 2024, the Company reviewed the carrying value of goodwill for impairment indicators. As a result of the review, there were no impairment indicators regarding the Company’s goodwill that required a quantitative test to be performed. However, our accounting estimates could materially change from period to period due to changing market factors. We will continue to monitor future events, changes in circumstances, and the potential impact thereof. If actual results are not consistent with our assumptions and estimates, we may be exposed to future goodwill impairment losses

23

Table of Contents

See Note 3 – Acquisition of White Oak Senior Living for further detail describing the goodwill and indefinite-lived intangible asset additions in 2024. At September 30, 2024, the following table represents the activity related to our goodwill by segment (in thousands):

|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
January 1, 2024 |  | $ | 3,741 |  |  | $ | 164,554 |  |  | $ | – |  |  | $ | 168,295 |
Additions |  |  | 1,395 |  |  |  | – |  |  |  | – |  |  |  | 1,395 |
September 30, 2024 |  | $ | 5,136 |  |  | $ | 164,554 |  |  | $ | – |  |  | $ | 169,690 |

Indefinite-lived intangible assets consist of the following (in thousands):

| September 30, 2024 |  |  | December 31, 2023
Trade names | $ | 15,836 |  |  | $ | 4,340
Certificates of need |  | 1,757 |  |  |  | 532
Licenses |  | 2,212 |  |  |  | 2,166
Total | $ | 19,805 |  |  | $ | 7,038

As part of the White Oak Senior Living acquisition, we recorded indefinite-lived intangible assets that consisted of the trade name ($11,496,000) and certificates of need and licenses ($1,271,000).

Note 13 - Stock Repurchase Program

During the nine months ended September 30, 2024, the Company repurchased 133,151 shares of its common stock for a total cost of $13,502,000. During the nine months ended September 30, 2023, the Company repurchased 44,349 shares of its common stock for a total cost of $2,482,000. The shares were funded from cash on hand and were cancelled and returned to the status of authorized but unissued.

Note 14 – Stock–Based Compensation

NHC recognizes stock–based compensation expense for all stock options granted over the requisite service period using the fair value at the date of grant using the Black–Scholes pricing model. Stock–based compensation totaled $1,093,000 and $708,000 for the three months ended September 30, 2024 and 2023, respectively. Stock-based compensation totaled $3,062,000 and $2,119,000 for the nine months ended September 30, 2024 and 2023, respectively. Stock–based compensation is included in “Salaries, wages and benefits” in the interim condensed consolidated statements of operations.

At September 30, 2024, the Company had $5,752,000 of unrecognized compensation cost related to unvested stock–based compensation awards. This unrecognized compensation cost will be amortized over an approximate two-year period.

Stock Options

The following table summarizes the significant assumptions used to value the options granted for the nine months ended September 30, 2024 and for the year ended December 31, 2023.

|  | September 30, 2024 |  |  | December 31, 2023 |
Risk–free interest rate |  |  | 4.40% |  |  |  | 4.52% |
Expected volatility |  |  | 24.1% |  |  |  | 29.3% |
Expected life, in years |  |  | 2.9 |  |  |  | 2.9 |
Expected dividend yield |  |  | 2.63% |  |  |  | 4.41% |

The following table summarizes our outstanding stock options for the nine months ended September 30, 2024 and for the year ended December 31, 2023.

|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value |
Options outstanding at January 1, 2023 |  |  | 445,144 |  |  | $ | 66.62 |  |  | $ | – |
Options granted |  |  | 299,278 |  |  |  | 54.44 |  |  |  | – |
Options exercised |  |  | (103,481 | ) |  |  | 64.72 |  |  |  | – |
Options cancelled |  |  | (52,407 | ) |  |  | 60.58 |  |  |  | – |
Options outstanding at December 31, 2023 |  |  | 588,534 |  |  |  | 61.30 |  |  |  | – |
Options granted |  |  | 298,097 |  |  |  | 94.42 |  |  |  | – |
Options exercised |  |  | (211,040 | ) |  |  | 63.75 |  |  |  | – |
Options cancelled |  |  | (33,202 | ) |  |  | 79.34 |  |  |  | – |
Options outstanding at September 30, 2024 |  |  | 642,389 |  |  |  | 74.93 |  |  | $ | 32,658,000 |
Options exercisable at September 30, 2024 |  |  | 153,439 |  |  |  | 63.87 |  |  | $ | 9,498,000 |

24

Table of Contents

Options Outstanding September 30, 2024 |  |  | Exercise Prices |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life in Years |
331,037 |  |  |  | 53.94 | - | 69.19 |  |  |  | 58.88 |  |  |  | 3.0 |
311,352 |  |  |  | 71.64 | - | 96.03 |  |  |  | 92.00 |  |  |  | 4.1 |
642,389 |  |  |  |  |  |  |  |  |  | 74.93 |  |  |  | 3.5 |

Note 15 – Long-Term Debt

Long–term debt consists of the following (dollars in thousands):

|  | Interest rate at September 30, 2024 |  |  | Maturity |  |  | September 30, 2024 |  |  | December 31, 2023 |
Credit facility, interest payable monthly |  |  | Variable, 6.8% |  |  |  | 2029 |  |  | $ | 147,000 |  |  | $ | – |
Less current portion |  |  |  |  |  |  |  |  |  |  | (7,500 | ) |  |  | – |
Total long-term debt |  |  |  |  |  |  |  |  |  | $ | 139,500 |  |  | $ | – |

On August 1, 2024, the Company entered into a $200,000,000 senior credit facility with a five-year term consisting of a $150,000,000 term facility and a $50,000,000 revolving line of credit (the “Credit Facility”). The Credit Facility is for general corporate purposes, including working capital and acquisitions. The loans bear interest at either (i) Term Secured Overnight Financing Rate (“SOFR”) for interest periods of one, three or six months, plus the applicable margin or, at NHC’s option, (ii) the Base Rate plus the applicable margin. The applicable margin is an interest rate per annum between 1.30% and 1.65% for Term SOFR loans and between .30% and .65% for Base Rate loans, depending upon the Company meeting certain conditions. The revolving line of credit contains a commitment fee equal to 0.25% of the unused borrowing capacity. There are no amounts outstanding on the revolving line of credit at September 30, 2024.

NHC’s obligations under the Credit Facility are unsecured. The Credit Facility contains customary representations and warranties, financial covenants, and other customary affirmative and negative covenants. The Credit Facility also contains customary events of default. As of September 30, 2024, the Company is compliant with all financial covenants. Based on level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt based upon the interest rates that the Company believes it can currently obtain for similar debt.

The aggregate maturities of long–term debt for the five years subsequent to September 30, 2024 are as follows (in thousands):

|  | Long–Term Debt |
2025 |  | $ | 7,500 |
2026 |  |  | 7,500 |
2027 |  |  | 7,500 |
2028 |  |  | 7,500 |
2029 |  |  | 117,000 |
Total |  | $ | 147,000 |

Note 16 – Income Taxes

The Company's income tax provision as a percentage of our income before income taxes was 26.4% and 27.9% for the three months ended September 30, 2024 and 2023, respectively.

The Company's income tax provision as a percentage of our income before income taxes was 26.3% and 28.3% for the nine months ended September 30, 2024 and 2023, respectively.

Typically, these percentages vary from the U.S. federal statutory income tax rate of 21% primarily due to state income taxes, excess tax benefits from stock-based compensation, benefits resulting from the lapsing of statute of limitations of items in our tax contingency reserve, and non-deductible expenses. For the three months and nine months ended September 30, 2024, the accrual of state income tax was the most significant reconciling item. For the three and nine months ended September 30, 2023, the accrual of state income tax was the only significant reconciling items.

25

Table of Contents

Our quarterly income tax provision, and our estimate of our annual effective income tax rate, is subject to variation due to several factors, including volatility based on the amount of pre-tax income or loss.

The Company is no longer subject to U.S. federal and state examinations by tax authorities for years before 2020 (with certain state exceptions).

Note 17 – Contingencies and Commitments

Accrued Risk Reserves

We have wholly–owned limited purpose insurance companies that insure risks related to workers’ compensation and general and professional liability insurance claims both for our owned and leased entities and certain of the entities to which we provide management or accounting services. The liability we have recognized for reported claims and estimates for incurred but unreported claims totals $110,204,000 and $103,259,000 at September 30, 2024 and December 31, 2023, respectively. The liability is included in accrued risk reserves in the interim condensed consolidated balance sheets and is subject to adjustment for actual claims incurred. It is possible that these claims plus unasserted claims could exceed our insurance coverages and our reserves, which could have a material adverse effect on our consolidated financial position, results of operations and cash flows.

As a result of the terms of our insurance policies and our use of wholly owned limited purpose insurance companies, we have retained significant insurance risk with respect to workers’ compensation and general and professional liability. We consider the professional services of independent actuaries to assist us in estimating our exposures for claims obligations (for both asserted and unasserted claims) related to deductibles and exposures in excess of coverage limits, and we maintain reserves for these obligations. Such estimates are based on many variables including historical and statistical information and other factors.

Workers’ Compensation

For workers’ compensation, we utilize a wholly–owned Tennessee domiciled property/casualty insurance company to write coverage for NHC affiliates and for third–party customers. Policies are written for a duration of twelve months and cover only risks related to workers’ compensation losses. All customers are companies which operate in the senior care industry. Business is written on a direct basis.

General and Professional Liability Insurance and Lawsuits

The senior care industry has experienced significant increases in both the number of personal injury/wrongful death claims and in the severity of awards based upon alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. Additional insurance is purchased through third party providers that serve to supplement the coverage provided through our wholly owned captive insurance company.

There is certain additional litigation incidental to our business, none of which, based upon information available to date, would be material to our financial position, results of operations, or cash flows. In addition, the long–term care industry is continuously subject to scrutiny by governmental regulators, which could result in litigation or claims related to regulatory compliance matters.

Qui Tam Litigation

United States of America, ex rel. Jennifer Cook and Sally Gaither v. Integrated Behavioral Health, Inc., NHC HealthCare/Moulton, LLC, et al., Case No. 2:20-CV-00877-AMM (N.D. Ala.) This is a qui tam case originally filed under seal on June 22, 2020. The United States declined intervention on March 1, 2021. Thereafter, the Plaintiffs filed an amended Complaint against Dr. Sanja Malhotra, Integrated Behavioral Health, Inc. and other entities that Dr. Malhotra was alleged to own or in which he allegedly had a financial interest. The Complaint also named multiple skilled nursing facilities as Defendants, including NHC Healthcare/Moulton, LLC, an affiliate of National HealthCare Corporation. The Complaint alleged that nurse practitioners affiliated with Dr. Malhotra provided free services to the facilities in exchange for referrals to entities owned by or in which Dr. Malhotra had a financial interest in violation of the False Claims Act and Anti-Kickback Statute. NHC Healthcare/Moulton, LLC denied the allegations and filed a motion to dismiss on November 4, 2021. On January 28, 2022, the district court stayed this matter and administratively terminated the motion to dismiss pending the U.S. Supreme Court's review of a petition for certiorari filed in an unrelated matter but involving one of the legal arguments raised in the motion to dismiss. Thereafter, the U.S. Supreme Court denied the petition for certiorari in the unrelated matter. As a result, NHC Healthcare/Moulton, LLC renewed its motion to dismiss. The District Court granted NHC Healthcare/Moulton’s Motion to Dismiss, along with other pending Motions to Dismiss, and entered an Order of Dismissal on March 23, 2023 and an Amended Order of Dismissal on April 4, 2023, which dismissed the case in its entirety with prejudice with respect to the claims asserted by the Plaintiffs. The Plaintiffs filed a Notice of Appeal on April 20, 2023 to appeal the dismissal to the United States Court of Appeals for the Eleventh Circuit. On December 21, 2023, the Eleventh Circuit entered an Order affirming the District Court’s dismissal of the claims. The time period for the Plaintiffs to file a Petition for a Writ of Certiorari with the United States Supreme Court has expired making the Order affirming dismissal issued by the Eleventh Circuit final.

26

Table of Contents

Civil Investigative Demand

On or about May 21, 2024, Caris Healthcare, L.P. (“Caris”) received a Civil Investigative Demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of Tennessee. The CID requests the production of certain medical records for patients at Caris’ Nashville office and other documents related to the billing for hospice services for the period of January 1, 2019, through the date of the CID. The Company is cooperating with respect to the requests and remains in the process of responding to the CID.

Governmental Regulations

Laws and regulations governing Medicare, Medicaid and other federal healthcare programs are complex and subject to interpretation. Management believes that it is following all applicable laws and regulations in all material respects. However, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusions from the Medicare, Medicaid and other federal healthcare programs.

Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward–Looking Statements

References throughout this document to the Company include National HealthCare Corporation and its wholly owned subsidiaries. In accordance with the Securities and Exchange Commissions “Plain English” guidelines, this Quarterly Report on Form 10–Q has been written in the first person. In this document, the words “we”, “our”, “ours” and “us” refer only to National HealthCare Corporation and its wholly–owned subsidiaries and not any other person.

This Quarterly Report on Form 10–Q and other information we provide from time to time, contains certain “forward–looking” statements as that term is defined by the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations or cash flows, continued performance improvements, ability to service and refinance our debt obligations, ability to finance growth opportunities, ability to control our patient care liability costs, ability to respond to changes in government regulations, ability to execute our three–year strategic plan, and similar statements including, without limitations, those containing words such as “believes”, “anticipates”, “expects”, “intends”, “estimates”, “plans”, and other similar expressions are forward–looking statements.

Forward–looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward–looking statements as a result of, but not limited to, the following factors:

● | national and local economic conditions, including their effect on the availability and cost of labor, utilities and materials;

● | the effect of government regulations and changes in regulations governing the healthcare industry, including our compliance with such regulations;

● | changes in Medicare and Medicaid payment levels and methodologies and the application of such methodologies by the government and its fiscal intermediaries;

● | liabilities and other claims asserted against us, including patient care liabilities, as well as the resolution of current litigation (see Note 17: Contingencies and Commitments);

● | the ability to attract and retain qualified personnel;

● | the availability and terms of capital to fund acquisitions and capital improvements;

27

Table of Contents

● | the competitive environment in which we operate;

● | our need to make investments continually in our processes and information systems to protect the privacy of patients, partners and other persons and reduce the risk of successful cybersecurity attacks;

● | damage to our reputation, regulatory penalties, legal claims and liability under state and federal laws that we could suffer upon any cybersecurity or privacy breaches;

● | the ability to maintain and increase census levels; and

● | demographic changes.

See the notes to the quarterly financial statements, and “Item 1. Business” in our 2023 Annual Report on Form 10–K for a discussion of various governmental regulations and other operating factors relating to the healthcare industry and the risk factors inherent in them. This may be found on our web site at www.nhccare.com. You should carefully consider these risks before making any investment in the Company. These risks and uncertainties are not the only ones facing us. There may be additional risks that we do not presently know of or that we currently deem immaterial. If any of the risks occur, our business, financial condition or results of operations could be materially adversely affected. In that case, the trading price of our shares of stock could decline, and you may lose all or part of your investment. Given these risks and uncertainties, we can give no assurances that these forward–looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them.

Overview

National HealthCare Corporation (“NHC” or the “Company”) is a leading provider of senior health care services. As of September 30, 2024, we operate or manage, through certain affiliates, 80 skilled nursing facilities with a total of 10,349 licensed beds, 26 assisted living facilities with 1,413 units, nine independent living facilities, three behavioral health hospitals, 34 homecare agencies, and 32 hospice agencies. We operate specialized care units within certain of our healthcare centers such as Alzheimer's disease care units and sub-acute nursing units. In addition, we provide insurance services, management and accounting services, and we lease properties to operators of skilled nursing and assisted living facilities. We operate in 9 states and are located primarily in the southeastern United States.

Centers for Medicare and Medicaid Services Minimum Staffing Standards

On April 22, 2024, the Centers for Medicare and Medicaid Services (“CMS”) issued the Minimum Staffing Standards for Long-Term Care (“LTC”) Facilities and Medicaid Institutional Payment Transparency Reporting final rule. Included in this final rule are new comprehensive minimum nurse staffing requirements, which aim to significantly reduce the risk of residents receiving unsafe and low-quality care within LTC facilities. CMS is finalizing a total nurse staffing standard of 3.48 hours per resident day (“HPRD”), which must include at least 0.55 HPRD of direct registered nurse (“RN”) care and 2.45 HPRD of direct nurse aide care. Facilities may use any combination of nurse staff (RN, licensed practical nurse and licensed vocational nurse, or nurse aide) to account for the additional 0.48 HPRD needed to comply with the total nurse staffing standard.

CMS is also finalizing enhanced facility assessment requirements and a requirement to have an RN onsite 24 hours a day, seven days a week (“24/7”), to provide skilled nursing care. The 24/7 RN onsite can be the Director of Nursing; however, they must be available to provide direct resident care.

This final rule provides a staggered implementation timeframe of the minimum nurse staffing standards and a 24/7 RN requirement based on geographic location, as well as possible exemptions for qualifying facilities for some parts of these requirements based on workforce unavailability and other factors.

Summary of Goals and Areas of Focus

Occupancy

A primary area of management focus continues to be the rates of occupancy within our skilled nursing facilities. The overall census in owned and leased skilled nursing facilities for the three months ending September 30, 2024 was 88.3% compared to 88.1% for the same period a year ago. For the nine months ended September 30, 2024, overall census in our owned and leased skilled nursing facilities was 88.6% compared to 87.8% for the same period a year ago.

28

Table of Contents

Due to America’s healthcare labor shortage, the challenge of maintaining desirable patient census levels has been amplified. Management has undertaken a number of steps in order to best position our current and future health care facilities. This includes working internally to examine and improve systems to be most responsive to referral sources and payors, as well as find creative initiatives to retain and attract qualified healthcare professionals. Additionally, NHC is in various stages of partnerships with hospital systems, payors, and other post–acute alliances to better position ourselves so we are an active participant in the delivery of post-acute healthcare services.

Quality of Patient Care

CMS introduced the Five-Star Quality Rating System to help consumers, their families and caregivers compare skilled nursing facilities more easily. The Five-Star Quality Rating System gives each skilled nursing operation a rating ranging between one and five stars in various categories (five stars being the best). The Company has always strived for patient-centered care and quality outcomes as precursors to outstanding financial performance.

The tables below summarize NHC's overall performance in these Five-Star ratings versus the skilled nursing industry as of September 30, 2024:

|  | NHC Ratings |  |  | Industry Ratings |
Total number of skilled nursing facilities, end of period |  |  | 80 |  |  |  |  |
Number of 4 and 5-star rated skilled nursing facilities |  |  | 45 |  |  |  |  |
Percentage of 4 and 5-star rated skilled nursing facilities |  |  | 56% |  |  |  | 36% |
Average rating for all skilled nursing facilities, end of period |  |  | 3.5 |  |  |  | 2.9 |

Development and Growth

We are undertaking to expand our senior care operations while protecting our existing operations and markets. The following table lists our recent development activities.

Type of Operation |  | Description |  | Size |  | Location |  | Placed in Service
Hospice |  | New Agency |  | 1 agency |  | Cedar Bluff, VA |  | March 2023
Skilled Nursing |  | Acquisition |  | 66 beds |  | Nashville, TN |  | May 2023
Homecare |  | New Agency |  | 1 agency |  | Tallahassee, FL |  | May 2023
Assisted Living Facility |  | New Operations |  | 135 units |  | Vero Beach, FL |  | July 2023
Assisted Living Facility |  | New Operations |  | 95 units |  | Merritt Island, FL |  | July 2023
Assisted Living Facility |  | New Operations |  | 100 units |  | Stuart, FL |  | July 2023
Hospice |  | New Agency |  | 1 agency |  | Morristown, TN |  | April 2024
Hospice |  | New Agency |  | 1 agency |  | Lawrenceburg, TN |  | July 2024
Hospice |  | New Agency |  | 1 agency |  | Wytheville, VA |  | August 2024

On August 1, 2024, the Company purchased the White Oak portfolio, including its long-term care pharmacy. The White Oak portfolio consists of 15 skilled nursing facilities, two assisted living facilities, and four independent living facilities. The White Oak operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina.

Accrued Risk Reserves

Our accrued professional liability and workers’ compensation reserves totaled $110,204,000 at September 30, 2024 and are a primary area of management focus. We have set aside restricted cash and cash equivalents and marketable securities to fund our estimated professional liability and workers’ compensation liabilities.

As to exposure for professional liability claims, we have developed performance certification criteria to measure and bring focus to the patient care issues most likely to produce professional liability exposure, including in–house acquired pressure ulcers, significant weight loss and numbers of falls. These programs for certification, which we regularly modify and improve, have produced measurable improvements in reducing these incidents. Our experience is that achieving goals in these patient care areas improves both patient and employee satisfaction.

29

Table of Contents

Government Reimbursement Programs

Medicare – Skilled Nursing Facilities

In July 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates and policy changes for skilled nursing facilities, which began on October 1, 2023. The fiscal year 2024 rule equates to a net increase of 4.0%, or approximately $1.4 billion, in Medicare Part A payments to SNFs in fiscal year 2024 compared to 2023 levels. The rule includes a 3.0% market basket rate increase, a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment, as well as a negative 2.3%, or approximately $789 million, decrease in 2024 SNF Payment Prospective Systems rates as a result of the second phase of the Patient Driven Payment Model parity adjustment recalibration.

In July 2024, CMS released its final rule outlining fiscal year 2025 Medicare payment rates and policy changes for skilled nursing facilities, which began on October 1, 2024. The fiscal year 2025 rule equates to a net 4.2% increase in Medicare Part A payments to SNFs in fiscal year 2025 compared to 2024 levels. The rule includes a market basket increase of 3.0%, an increase of 1.7% to the market basket forecast error adjustment, and a negative 0.5% productivity adjustment. This final rule also changes CMS’ enforcement policies to impose more equitable and consistent civil monetary penalties ("CMPs") for health and safety violations as part of the agency’s ongoing work to increase the safety and care provided in America’s nursing homes. CMS revised the regulation to expand the type of CMPs that can be imposed to allow for more per instance and per day CMPs to be imposed, as appropriate. In the final rule it also finalized updates to the SNF Quality Reporting Program ("QRP") to better account for adverse social conditions that negatively impact individuals’ health or healthcare. CMS also finalized its proposal to adopt a data validation process for the SNF QRP beginning the same year.

For the first nine months of 2024, our average Medicare per diem rate for skilled nursing facilities increased 4.9% as compared to the same period in 2023.

Medicaid – Skilled Nursing Facilities

Effective July 1, 2024 and for the fiscal year 2025, the state of Tennessee implemented specific individual nursing facility increases. We estimate the resulting increase in revenue for the 2025 fiscal year will be approximately $11,000,000 annually, or $2,750,000 per quarter. Additionally, the state of Tennessee implemented non-recurring rate increases for fiscal year 2025 for continued stabilization payments and Medicaid rate rebasing. These non-recurring rate increases will result in an additional increase in revenue for the 2025 fiscal year of approximately $8,200,000 annually, or $2,050,000 per quarter.

Effective October 1, 2024 and for the fiscal year 2025, the state of South Carolina implemented specific individual nursing facility increases. We estimate the resulting increase in revenue for the 2025 fiscal year will be approximately $500,000 annually, or $125,000 per quarter.

Effective July 1, 2024 and for the fiscal year 2025, the state of Missouri has proposed specific individual nursing facility increases, subject to approval from Centers for Medicare and Medicaid Services ("CMS"). Upon CMS' approval, we estimate the resulting increase in revenue for the 2025 fiscal year will be approximately $6,600,000 annually, or $1,650,000 per quarter.

We have also received from many of the states in which we operate a supplemental Medicaid payment to help mitigate the inflationary labor and medical supplies costs resulting from the pandemic. We have recorded $5,267,000 and $4,232,000 in net patient revenues for these supplemental Medicaid payments for the three months ended September 30, 2024 and 2023, respectively. We have recorded $11,314,000 and $15,3620,000 in net patient revenues for these supplemental Medicaid payments for the nine months ended September 30, 2024 and 2023, respectively.

For the first nine months of 2024, our average Medicaid per diem increased 10.2% compared to the same period in 2023.

State Medicaid plans subject to budget constraints are of particular concern to us. Changes in federal funding coupled with state budget problems and Medicaid expansion under the Affordable Care Act have produced an uncertain environment. Some states will not keep pace with post-acute healthcare inflation. States are currently under pressure to pursue other alternatives to skilled nursing care such as community and home–based services. Medicaid programs are funded jointly by the federal government and the states and are administered by states under approved plans. Most state Medicaid payments are made under a prospective payment system or under programs which negotiate payment levels with individual providers. Some states use, or have applied to use, waivers granted by CMS to implement expansion, impose different eligibility or enrollment restrictions, or otherwise implement programs that vary from federal standards.

Medicare – Homecare Programs

In November 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates. CMS projects payments to home health agencies in fiscal year 2024 will increase in aggregate by 0.8%, or $140 million. The increase is the result of a 3.3% market basket update, reduced by a 0.3% productivity adjustment. The increase is offset by a behavioral adjustment that will cut payments by a net 2.6%. The behavioral adjustment was designed to achieve budget-neutral implementation of the PDPM. Finally, CMS also adjusted the fixed-dollar loss ratio for outlier payments, which will increase payments by 0.4%.

In June 2024, CMS released its proposed rule outlining fiscal year 2025 Medicare payment rates. CMS projects payments to home health agencies in fiscal year 2025 will decrease by 1.7% or $280 million, relative to the prior year. This decrease reflects a 2.5% home health payment update, reduced by a 3.6% decrease related to the Patient-Driven Groupings Model (“PDGM”) rebalancing and an estimated 0.6% decrease that reflects a proposed fixed dollar loss for outlier payments. As required by the Bipartisan Budget Act of 2018, this rule proposes a permanent prospective adjustment to the CY2025 home health payment rate to account for the impact of implementing the PDGM. This adjustment accounts for differences between assumed behavior changes and actual behavior changes on estimated aggregate expenditures due to the CY2020 implementation of PDGM and the change to a 30-day unit of payment.

30

Table of Contents

Medicare – Hospice

In July 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates. CMS issued a rate increase of 3.1%, or $780 million, effective October 1, 2023. This increase is the result of a 3.3% market basket increase reduced by a 0.2% productivity adjustment. The FY2024 hospice payment update also includes an update to the statutory aggregate cap amount, which limits the overall payments per patient that are made annually. The cap amount for FY2024 is $33,494.

In July 2024, CMS released its final rule outlining fiscal year 2025 Medicare payment rates. CMS issued a rate increase of 2.9%, or $790 million, effective October 1, 2024. This increase is the result of a 3.4% market basket increase reduced by a 0.5% productivity adjustment. The FY2025 hospice payment update also includes an update to the statutory aggregate cap amount, which limits the overall payments per patient that are made annually. The cap amount for FY2025 is $34,465.

Segment Reporting

The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals; and (2) homecare and hospice services. These reportable operating segments are consistent with information used by the Company’s Chief Executive Officer, as chief operating decision maker (“CODM”), to assess performance and allocate resources. The Company also reports an “all other” category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office.

The Company’s CODM evaluates performance and allocates capital resources to each segment based on an operating model that is designed to improve the quality of patient care and profitability of the Company while enhancing long-term shareholder value. The CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below.

The following table sets forth the Company’s unaudited interim condensed consolidated statements of operations by business segment (in thousands):

|  | Three Months Ended September 30, 2024 |
|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 293,026 |  |  | $ | 35,648 |  |  | $ | - |  |  | $ | 328,674 |
Other revenues |  |  | 370 |  |  |  | - |  |  |  | 11,154 |  |  |  | 11,524 |
Net operating revenues |  |  | 293,396 |  |  |  | 35,648 |  |  |  | 11,154 |  |  |  | 340,198 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 175,241 |  |  |  | 21,456 |  |  |  | 16,698 |  |  |  | 213,395 |
Other operating |  |  | 72,384 |  |  |  | 6,612 |  |  |  | 3,513 |  |  |  | 82,509 |
Rent |  |  | 8,422 |  |  |  | 602 |  |  |  | 1,862 |  |  |  | 10,886 |
Depreciation and amortization |  |  | 9,632 |  |  |  | 172 |  |  |  | 815 |  |  |  | 10,619 |
Interest |  |  | 1,742 |  |  |  | - |  |  |  | - |  |  |  | 1,742 |
Total costs and expenses |  |  | 267,421 |  |  |  | 28,842 |  |  |  | 22,888 |  |  |  | 319,151 |
Income/(loss) from operations |  |  | 25,975 |  |  |  | 6,806 |  |  |  | (11,734 | ) |  |  | 21,047 |
Non-operating income |  |  | - |  |  |  | - |  |  |  | 4,224 |  |  |  | 4,224 |
Unrealized gains on marketable equity securities |  |  | - |  |  |  | - |  |  |  | 32,767 |  |  |  | 32,767 |
Income before income taxes |  | $ | 25,975 |  |  | $ | 6,806 |  |  | $ | 25,257 |  |  | $ | 58,038 |

31

Table of Contents

|  | Three Months Ended September 30, 2023 |
|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 243,865 |  |  | $ | 33,140 |  |  | $ | - |  |  | $ | 277,005 |
Other revenues |  |  | 297 |  |  |  | - |  |  |  | 11,183 |  |  |  | 11,480 |
Net operating revenues |  |  | 244,162 |  |  |  | 33,140 |  |  |  | 11,183 |  |  |  | 288,485 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 151,912 |  |  |  | 20,066 |  |  |  | 10,686 |  |  |  | 182,664 |
Other operating |  |  | 64,228 |  |  |  | 5,868 |  |  |  | 2,394 |  |  |  | 72,490 |
Rent |  |  | 8,186 |  |  |  | 538 |  |  |  | 1,370 |  |  |  | 10,094 |
Depreciation and amortization |  |  | 9,203 |  |  |  | 185 |  |  |  | 747 |  |  |  | 10,135 |
Interest |  |  | 77 |  |  |  | - |  |  |  | - |  |  |  | 77 |
Total costs and expenses |  |  | 233,606 |  |  |  | 26,657 |  |  |  | 15,197 |  |  |  | 275,460 |
Income/(loss) from operations |  |  | 10,556 |  |  |  | 6,483 |  |  |  | (4,014 | ) |  |  | 13,025 |
Non-operating income |  |  | - |  |  |  | - |  |  |  | 4,097 |  |  |  | 4,097 |
Unrealized losses on marketable equity securities |  |  | - |  |  |  | - |  |  |  | (3,093 | ) |  |  | (3,093 | )
Income/(loss) before income taxes |  | $ | 10,556 |  |  | $ | 6,483 |  |  | $ | (3,010 | ) |  | $ | 14,029 |

|  | Nine Months Ended September 30, 2024 |
|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 790,664 |  |  | $ | 103,751 |  |  | $ | - |  |  | $ | 894,415 |
Other revenues |  |  | 710 |  |  |  | - |  |  |  | 33,462 |  |  |  | 34,172 |
Government stimulus income |  |  | - |  |  |  | - |  |  |  | 9,445 |  |  |  | 9,445 |
Net operating revenues and grant income |  |  | 791,374 |  |  |  | 103,751 |  |  |  | 42,907 |  |  |  | 938,032 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 474,190 |  |  |  | 63,761 |  |  |  | 38,658 |  |  |  | 576,609 |
Other operating |  |  | 207,883 |  |  |  | 18,977 |  |  |  | 11,232 |  |  |  | 238,092 |
Rent |  |  | 24,795 |  |  |  | 1,736 |  |  |  | 5,273 |  |  |  | 31,804 |
Depreciation and amortization |  |  | 27,646 |  |  |  | 545 |  |  |  | 2,352 |  |  |  | 30,543 |
Interest |  |  | 1,788 |  |  |  | - |  |  |  | - |  |  |  | 1,788 |
Total costs and expenses |  |  | 736,302 |  |  |  | 85,019 |  |  |  | 57,515 |  |  |  | 878,836 |
Income/(loss) from operations |  |  | 55,072 |  |  |  | 18,732 |  |  |  | (14,608 | ) |  |  | 59,196 |
Non-operating income |  |  | - |  |  |  | - |  |  |  | 14,865 |  |  |  | 14,865 |
Unrealized gains on marketable equity securities |  |  | - |  |  |  | - |  |  |  | 56,290 |  |  |  | 56,290 |
Income before income taxes |  | $ | 55,072 |  |  | $ | 18,732 |  |  | $ | 56,547 |  |  | $ | 130,351 |

32

Table of Contents

|  | Nine Months Ended September 30, 2023 |
|  | Inpatient Services |  |  | Homecare and Hospice |  |  | All Other |  |  | Total |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net patient revenues |  | $ | 706,795 |  |  | $ | 97,822 |  |  | $ | - |  |  | $ | 804,617 |
Other revenues |  |  | 894 |  |  |  | - |  |  |  | 35,119 |  |  |  | 36,013 |
Net operating revenues |  |  | 707,689 |  |  |  | 97,822 |  |  |  | 35,119 |  |  |  | 840,630 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 435,517 |  |  |  | 60,804 |  |  |  | 29,461 |  |  |  | 525,782 |
Other operating |  |  | 192,473 |  |  |  | 17,356 |  |  |  | 7,384 |  |  |  | 217,213 |
Rent |  |  | 24,520 |  |  |  | 1,639 |  |  |  | 3,928 |  |  |  | 30,087 |
Depreciation and amortization |  |  | 27,474 |  |  |  | 555 |  |  |  | 2,237 |  |  |  | 30,266 |
Interest |  |  | 268 |  |  |  | - |  |  |  | - |  |  |  | 268 |
Total costs and expenses |  |  | 680,252 |  |  |  | 80,354 |  |  |  | 43,010 |  |  |  | 803,616 |
Income/(loss) from operations |  |  | 27,437 |  |  |  | 17,468 |  |  |  | (7,891 | ) |  |  | 37,014 |
Non-operating income |  |  | - |  |  |  | - |  |  |  | 12,116 |  |  |  | 12,116 |
Unrealized gains on marketable equity securities |  |  | - |  |  |  | - |  |  |  | 2,943 |  |  |  | 2,943 |
Income before income taxes |  | $ | 27,437 |  |  | $ | 17,468 |  |  | $ | 7,168 |  |  | $ | 52,073 |

33

Table of Contents

Non-GAAP Financial Presentation

The Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company’s operations and measure the Company’s performance more consistently across periods. Therefore, the Company believes this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

Specifically, the Company believes the presentation of non-GAAP financial information that excludes the unrealized gains or losses on our marketable equity securities, operating results for newly opened facilities or agencies not at full capacity, gains on sale of unconsolidated companies, share-based compensation expense, acquisition-related expenses, and the recognition of the employee retention credit is helpful in allowing investors to assess the Company’s operations more accurately.

The operating results for newly opened facilities or agencies not at full capacity include newly constructed healthcare facilities or agencies that are still considered in the start-up phase, which are two hospice agencies for the three and nine months ended September 30, 3024. For the three and nine months ended September 30, 2023, included are two behavioral health hospitals, two homecare agencies, and two hospice agencies. The acquisition-related expenses represent expenses incurred to acquire the White Oak portfolio.

The tables below provide reconciliations of GAAP to non-GAAP items (dollars in thousands, except per share data):

|  | Three Months Ended September 30 |  |  | Nine Months Ended September 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net income attributable to National Healthcare Corporation |  | $ | 42,789 |  |  | $ | 10,388 |  |  | $ | 95,846 |  |  | $ | 38,392 |
Non-GAAP adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unrealized (gains)/losses on marketable equity securities |  |  | (32,767 | ) |  |  | 3,093 |  |  |  | (56,290 | ) |  |  | (2,943 | )
Operating results for newly opened facilities or agencies not at full capacity |  |  | 120 |  |  |  | 66 |  |  |  | 140 |  |  |  | 1,616 |
Share-based compensation expense |  |  | 1,093 |  |  |  | 708 |  |  |  | 3,062 |  |  |  | 2,119 |
Gain on sale of unconsolidated company |  |  | - |  |  |  | - |  |  |  | (1,024 | ) |  |  | - |
Acquisition-related expenses |  |  | 637 |  |  |  | - |  |  |  | 2,831 |  |  |  | - |
Employee retention credit |  |  | - |  |  |  | - |  |  |  | (9,445 | ) |  |  | - |
Income tax expense/(benefit) on non-GAAP adjustments |  |  | 8,038 |  |  |  | (1,005 | ) |  |  | 15,789 |  |  |  | (206 | )
Non-GAAP Net income |  | $ | 19,910 |  |  | $ | 13,250 |  |  | $ | 50,909 |  |  | $ | 38,978 |
GAAP diluted earnings per share |  | $ | 2.73 |  |  | $ | 0.68 |  |  | $ | 6.15 |  |  | $ | 2.51 |
Non-GAAP adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unrealized (gains)/losses on marketable equity securities |  |  | (1.55 | ) |  |  | 0.15 |  |  |  | (2.67 | ) |  |  | (0.14 | )
Operating results for newly opened facilities or agencies not at full capacity |  |  | 0.01 |  |  |  | - |  |  |  | 0.01 |  |  |  | 0.07 |
Share-based compensation expense |  |  | 0.05 |  |  |  | 0.03 |  |  |  | 0.15 |  |  |  | 0.10 |
Gain on sale of unconsolidated company |  |  | - |  |  |  | - |  |  |  | (0.05 | ) |  |  | - |
Acquisition-related expenses |  |  | 0.03 |  |  |  | - |  |  |  | 0.13 |  |  |  | - |
Employee retention credit |  |  | - |  |  |  | - |  |  |  | (0.45 | ) |  |  | - |
Non-GAAP diluted earnings per share |  | $ | 1.27 |  |  | $ | 0.86 |  |  | $ | 3.27 |  |  | $ | 2.54 |

34

Table of Contents

Results of Operations

The following table and discussion set forth items from the interim condensed consolidated statements of operations as a percentage of net operating revenues and grant income for the three and nine months ended September 30, 2024 and 2023.

Percentage of Net Operating Revenues

|  | Three Months Ended September 30 |  |  | Nine Months Ended June 30 |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net operating revenues and grant income |  |  | 100.0 | % |  |  | 100.0 | % |  |  | 100 | % |  |  | 100 | %
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries, wages, and benefits |  |  | 62.7 |  |  |  | 63.3 |  |  |  | 61.5 |  |  |  | 62.5 |
Other operating |  |  | 24.3 |  |  |  | 25.1 |  |  |  | 25.4 |  |  |  | 25.8 |
Facility rent |  |  | 3.2 |  |  |  | 3.5 |  |  |  | 3.4 |  |  |  | 3.6 |
Depreciation and amortization |  |  | 3.1 |  |  |  | 3.5 |  |  |  | 3.3 |  |  |  | 3.6 |
Interest |  |  | 0.5 |  |  |  | 0.1 |  |  |  | 0.1 |  |  |  | 0.1 |
Total costs and expenses |  |  | 93.8 |  |  |  | 95.5 |  |  |  | 93.7 |  |  |  | 95.6 |
Income from operations |  |  | 6.2 |  |  |  | 4.5 |  |  |  | 6.3 |  |  |  | 4.4 |
Non–operating income |  |  | 1.3 |  |  |  | 1.4 |  |  |  | 1.5 |  |  |  | 1.4 |
Unrealized gains/(losses) on marketable equity securities |  |  | 9.6 |  |  |  | (1.0 | ) |  |  | 6.1 |  |  |  | 0.4 |
Income before income taxes |  |  | 17.1 |  |  |  | 4.9 |  |  |  | 13.9 |  |  |  | 6.2 |
Income tax provision |  |  | (4.5 | ) |  |  | (1.4 | ) |  |  | (3.7 | ) |  |  | (1.8 | )
Net income |  |  | 12.6 |  |  |  | 3.5 |  |  |  | 10.2 |  |  |  | 4.4 |
Net income attributable to noncontrolling interest |  |  | 0.0 |  |  |  | 0.1 |  |  |  | 0.0 |  |  |  | 0.2 |
Net income attributable to stockholders of NHC |  |  | 12.6 |  |  |  | 3.6 |  |  |  | 10.2 |  |  |  | 4.6 |

Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023

Results for the quarter ended September 30, 2024 compared to the third quarter of 2023 include a 17.9% increase in net operating revenues. For the quarter ended September 30, 2024, GAAP net income attributable to NHC was $42,789,000 compared to $10,388,000 for the same period in 2023. Excluding the unrealized gains and losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended September 30, 2024 was $19,910,000 compared to $13,250,000 for the same period in 2023. The increase in adjusted net income for the three months ended September 30, 2024 compared to the same period of 2023 was primarily due to the per diem increases in our skilled nursing facilities and the continued reduction of nurse agency staffing expense within our operations.

On August 1, 2024, the Company purchased the White Oak portfolio, including its long-term care pharmacy. The White Oak portfolio consists of 15 skilled nursing facilities, two assisted living facilities, and four independent living facilities. The White Oak operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina.

Net operating revenues

Net patient revenues increased $51,669,000, or 18.7%, compared to the same period last year.

The total census at owned and leased skilled nursing facilities for the quarter averaged 88.3%, compared to an average of 88.1% for the same quarter a year ago. Overall, the composite skilled nursing facility per diem increased 7.8% compared to the same quarter a year ago. Our Medicare per diem rates increased 4.8% and managed care per diem rates decreased 6.0% compared to the same quarter a year ago. Medicaid and private pay per diem rates increased 13.1% and 14.1%, respectively, compared to the same quarter a year ago. For the three months ended September 30, 2024 and 2023, respectively, $5,267,000 and $4,232,000 have been included in our net patient revenues for supplemental Medicaid payments that are in addition to our Medicaid skilled nursing per diems.

White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $37,299,000 in net patient revenues for the quarter ended September 30, 2024 compared to the same quarter in the prior year.

On March 1, 2024, the Company exited a lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in net patient revenues decreasing $7,861,000 for the quarter ended September 30, 2024 compared to the same quarter in the prior year.

Other revenues decreased $44,000, or 0.4%, compared to the same quarter last year, as further detailed in Note 5 to our interim condensed consolidated financial statements.

35

Table of Contents

Total costs and expenses

Total costs and expenses for the three months ended September 30, 2024 compared to the same period of 2023 increased $43,691,000, or 15.9%, to $319,151,000 from $275,460,000.

Salaries, wages, and benefits as a percentage of net operating revenues was 62.7% compared to 63.3% for the three months ended September 30, 2024 and 2023, respectively. We continue to work diligently to find solutions to reduce and eliminate the agency nurse staffing within our healthcare operations. Our agency staffing expense decreased approximately 60% for the three months ended September 30, 2024 compared to the same period of 2023.

White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $24,511,000 in salaries, wages, and benefits for the quarter ended September 30, 2024 compared to the same quarter in the prior year.

On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in salaries, wages, and benefits decreasing $6,148,000 for the quarter ended September 30, 2024 compared to the same quarter in the prior year.

Other operating expenses as a percentage of net operating revenues was 24.3% and 25.1% for the three months ended September 30, 2024 and 2023, respectively. White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $8,238,000 in other operating expenses for the quarter ended September 30, 2024 compared to the same quarter in the prior year.

On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in other operating expenses decreasing $2,316,000 for the quarter ended September 30, 2024 compared to the same quarter in the prior year.

Other income

Non–operating income increased by $127,000 compared to the same period last year, as further detailed in Note 6 to our interim condensed consolidated financial statements.

Income taxes

The income tax provision for the three months ended September 30, 2024 is $15,338,000 (an effective income tax rate of 26.4%).

Noncontrolling interest

The noncontrolling interest in subsidiaries is presented within total equity of the Company’s consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its consolidated statements of operations. The Company’s earnings per share is calculated based on net income attributable to NHC’s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023

Results for the nine months ended September 30, 2024 compared to the same period of 2023 include an 11.6% increase in net operating revenues and grant income. For the nine months ended September 30, 2024, GAAP net income attributable to NHC was $95,846,000 compared to $38,392,000 for the same period in 2023. Excluding the unrealized gains in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the nine months ended September 30, 2024 was $50,909,000 compared to $38,978,000 for the same period in 2023. The increase in adjusted net income for the nine months ended September 30, 2024 compared to the same period of 2023 was primarily due to the per diem increases in our skilled nursing facilities and the continued reduction of nurse agency staffing expense within our operations.

On August 1, 2024, the Company purchased the White Oak portfolio, including its long-term care pharmacy. The White Oak portfolio consists of 15 skilled nursing facilities, two assisted living facilities, and four independent living facilities. The White Oak operations have 1,928 licensed skilled nursing beds, 48 assisted living units, and 302 independent living units in the states of South Carolina and North Carolina.

36

Table of Contents

Net operating revenues and grant income

Net patient revenues increased $89,798,000, or 11.2%, compared to the same period last year.

The total census at owned and leased skilled nursing facilities for the nine months ended September 30, 2024 averaged 88.6%, compared to an average of 87.8% for the same period a year ago. Overall, the composite skilled nursing facility per diem increased 7.7% compared to the same period a year ago. Our Medicare per diem rates increased 4.9% and managed care per diem rates decreased 0.1% compared to the same period a year ago. Medicaid and private pay per diem rates increased 10.2% and 12.9%, respectively, compared to the same period a year ago. For the nine months ended September 30, 2024 and 2023, respectively, $11,314,000 and $15,362,000 have been included in our net patient revenues for supplemental Medicaid payments that are in addition to our Medicaid skilled nursing per diems.

White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $37,299,000 in net patient revenues for the nine months ended September 30, 2024 compared to the same period in the prior year.

On March 1, 2024, the Company exited a lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in net patient revenues decreasing $18,799,000 for the nine months ended September 30, 2024 compared to the same period in the prior year.

Other revenues decreased $1,841,000, or 5.1%, compared to the same period last year, as further detailed in Note 5 to our interim condensed consolidated financial statements.

During the nine months ended September 30, 2024, the Company recognized $9,445,000 related to the Employee Retention Credit (“ERC”) that was established by the CARES Act and intended to help businesses retain their workforce and avoid layoffs during the pandemic. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. During the second quarter of 2024, all conditions related to the assistance were met and the credit was recognized as government stimulus income.

Total costs and expenses

Total costs and expenses for the nine months ended September 30, 2024 compared to the same period of 2023 increased $75,220,000, or 9.4%, to $878,836,000 from $803,616,000.

Salaries, wages, and benefits as a percentage of net operating revenues was 61.5% compared to 62.5% for the nine months ended September 30, 2024 and 2023, respectively. We continue to work diligently to find solutions to reduce and eliminate the agency nurse staffing within our healthcare operations. Our agency staffing expense decreased approximately 55% for the nine months ended September 30, 2024 compared to the same period of 2023.

White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $24,511,000 in salaries, wages, and benefits for the nine months ended September 30, 2024 compared to the same period in the prior year.

On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in salaries, wages, and benefits decreasing $14,097,000 for the nine months ended September 30, 2024 compared to the same period in the prior year.

Other operating expenses as a percentage of net operating revenues was 25.4% and 25.8% for the nine months ended September 30, 2024 and 2023, respectively. White Oak, which was acquired on August 1, 2024, as noted above, attributed to an increase of $8,238,000 in other operating expenses for the nine months ended September 30, 2024 compared to the same period in the prior year.

On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in other operating expenses decreasing $4,452,000 for the nine months ended September 30, 2024 compared to the same quarter in the prior year.

Other income

Non–operating income increased by $2,749,000 compared to the same period last year, as further detailed in Note 6 to our interim condensed consolidated financial statements.

Income taxes

The income tax provision for the nine months ended September 30, 2024 is $34,294,000 (an effective income tax rate of 26.3%).

37

Table of Contents

Liquidity, Capital Resources, and Financial Condition

Our primary sources of cash include revenues from the operations of our healthcare and senior living facilities, management and accounting services, rental income, and investment income. Our primary uses of cash include salaries, wages and other operating costs of our healthcare and senior living facilities, the cost of additions to and acquisitions of real property, facility rent expenses, and dividend distributions. These sources and uses of cash are reflected in our interim condensed consolidated statements of cash flows and are discussed in further detail below.

The following is a summary of our sources and uses of cash flows (dollars in thousands):

|  | Nine Months Ended September 30 |  |  | Six Month Change |
|  | 2024 |  |  | 2023 |  |  | $ |  |  | % |
Cash, cash equivalents, restricted cash, and restricted cash equivalents, at beginning of period |  | $ | 125,968 |  |  | $ | 74,865 |  |  | $ | 51,103 |  |  |  | 68.3 | %
Cash provided by operating activities |  |  | 94,514 |  |  |  | 85,483 |  |  |  | 9,031 |  |  |  | 10.6 |
Cash used in investing activities |  |  | (225,048 | ) |  |  | (7,382 | ) |  |  | (217,666 | ) |  |  | (2,948.6 | )
Cash provided by/(used in) financing activities |  |  | 119,640 |  |  |  | (32,711 | ) |  |  | 152,351 |  |  |  | 465.7 |
Cash, cash equivalents, restricted cash, and restricted cash equivalents, at end of period |  | $ | 115,074 |  |  | $ | 120,255 |  |  | $ | (5,181 | ) |  |  | (4.3 | )%

Operating Activities

Net cash provided by operating activities for the nine months ended September 30, 2024 was $94,514,000 as compared to $85,483,000 in the same period last year. Cash provided by operating activities consisted of net income of $96,057,000 and adjustments for non–cash items of $9,070,000. There was cash provided by working capital in the amount of $7,015,000 for the nine months ended September 30, 2024 compared to $20,645,000 for the same period a year ago.

Included in the adjustments for non-cash items are depreciation and amortization expense, equity in earnings of unconsolidated investments, unrealized gains on our marketable equity securities, gains on sales of investments, deferred taxes, and stock compensation.

Investing Activities

Net cash used in investing activities totaled $225,048,000 for the nine months ended September 30, 2024, compared to $7,382,000 for the nine months ended September 30, 2023. Cash used for property and equipment additions was $19,944,000 and $19,300,000 for the nine months ended September 30, 2024, and 2023, respectively. On August 1, 2024, the acquisition of White Oak Senior Living resulted in cash used of $215,896,000. Proceeds from the sale of marketable securities, net of purchases, resulted in cash provided by investing activity of $15,040,000 and $14,815,000 for the nine months ended September 30, 2024 and 2023, respectively. In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency resulting in proceeds from the sale of $2,100,000. For the nine months ended September 30, 2024, we contributed capital of $8,370,000 to a joint venture, multi-family development that is under construction in Franklin, Tennessee.

Financing Activities

Net cash provided by financing activities totaled $119,640,000 for the nine months ended September 30, 2024 compared to net cash used of $32,711,000 for the nine months ended September 30, 2023. The funding for the White Oak acquisition was provided by the Company’s cash on hand and borrowings under the credit facility of approximately $150,000,000. During the third quarter of 2024, cash of $3,000,000 was used to pay down the outstanding principal balance on our credit facility. We made principal payments under our finance lease obligations in the amount of $860,000 and $3,711,000 for the nine months ended September 30, 2024 and 2023, respectively. Cash used for dividend payments to common stockholders totaled $27,545,000 in the current year period compared to $26,520,000 for the same period a year ago. Cash provided by the issuance of common stock totaled $13,471,000 for the nine months ended September 30, 2024 compared to $260,000 for the same period a year ago. We repurchased common shares outstanding in the amount of $13,502,000 and $2,482,000 for the nine months ended September 30, 2024 and 2023, respectively.

38

Table of Contents

Short–term liquidity

We expect to meet our short-term liquidity requirements primarily from our cash flows from operating activities. In addition to cash flows from operations, our current cash on hand of $84,807,000, our marketable equity securities of $164,754,000, and our borrowing capacity on the $50 million available line of credit are expected to be adequate to meet our contractual obligations, operating liquidity, and our growth and development plans in the next twelve months. We also have substantial value in our unencumbered real estate assets, which could potentially be used as collateral in future borrowing opportunities.

Long–term liquidity

We expect to meet our long-term liquidity requirements primarily from our cash flows from operating activities, our current cash on hand of $84,807,000, our marketable equity securities of $164,754,000, and our borrowing capacity on the $50 million available line of credit. We also have substantial value in our unencumbered real estate assets, which could potentially be used as collateral in future borrowing opportunities.

Our ability to meet our long–term contractual obligations, and to finance our operating requirements and growth plans will depend upon our future performance. Our future performance will be affected by business, economic, financial and other factors, including potential changes in state and federal government payment rates for healthcare, customer demand, success of our marketing efforts, pressures from competitors, and the state of the economy, including the state of financial and credit markets, as well as many unforeseen factors.

Commitment and Contingencies

Governmental Regulations

Laws and regulations governing Medicare, Medicaid and other federal healthcare programs are complex and subject to interpretation. Management believes that it is following all applicable laws and regulations in all material respects. However, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusions from the Medicare, Medicaid, and other federal healthcare programs.

Item 3. | Quantitative and Qualitative Disclosures About Market Risk.

Market risk represents the potential economic loss arising from adverse changes in the fair value of financial instruments. Currently, our exposure to market risk relates primarily to our fixed–income and equity portfolios. These investment portfolios are exposed primarily to, but not limited to, interest rate risk, credit risk, equity price risk, and concentration risk. We also have exposure to market risk that includes our cash and cash equivalents. The Company's senior management has established comprehensive risk management policies and procedures to manage these market risks.

Interest Rate Risk

The fair values of our fixed–income investments fluctuate in response to changes in market interest rates. Increases and decreases in prevailing interest rates generally translate into decreases and increases, respectively, in the fair values of those instruments. Additionally, the fair values of interest rate sensitive instruments may be affected by the creditworthiness of the issuer, prepayment options, the liquidity of the instrument and other general market conditions. At September 30, 2024, we have available for sale marketable debt securities in the amount of $123,911,000. The fixed maturity portfolio is comprised of investments with primarily short–term and intermediate–term maturities. The fixed maturity portfolio allows our insurance company subsidiaries to achieve an adequate risk–adjusted return while maintaining sufficient liquidity to meet obligations.

As of September 30, 2024, our credit facility bears interest at variable interest rates. Currently, we have an outstanding balance on our credit facility of $147.0 million. Based on our outstanding balance on the credit facility, a 1% change in interest rates would change interest cost by approximately $1,470,000.

Our cash and cash equivalents consist of highly liquid investments with a maturity of less than three months when purchased. As a result of the short–term nature of our cash instruments, a hypothetical 1% change in interest rates would have minimal impact on our future earnings and cash flows related to these instruments.

We do not currently use any derivative instruments to hedge our interest rate exposure. We have not used derivative instruments for trading purposes and the use of such instruments in the future would be subject to approvals by the Investment Committee of the Board of Directors.

Credit Risk

Credit risk is managed by diversifying the fixed maturity portfolio to avoid concentrations in any single industry group or issuer and by limiting investments in securities with lower credit ratings.

39

Table of Contents

Equity Price and Concentration Risk

Our marketable equity securities are recorded at their fair market value based on quoted market prices. Thus, there is exposure to equity price risk, which is the potential change in fair value due to a change in quoted market prices. At September 30, 2024, the fair value of our marketable equity securities is approximately $187,755,000. Of the $187.8 million equity securities portfolio, our investment in NHI comprises approximately $137.1 million, or 73.0%, of the total fair value. We manage our exposure to NHI by closely monitoring the financial condition, performance, and outlook of the company. Hypothetically, a 10% change in quoted market prices would result in a related increase or decrease in the fair value of our equity investments of approximately $18.8 million. At September 30, 2024, our equity securities had net unrealized gains of $139.9 million. Of the $139.9 million of unrealized gains, $112.3 million is related to our investment in NHI.

Item 4. | Controls and Procedures.

As of September 30, 2024, an evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2024.

As permitted by guidance issued by the SEC that an assessment of internal control over financial reporting of a recently acquired business may be omitted from management's evaluation of disclosure controls and procedures, management excluded an assessment of the internal controls of White Oak Senior Living, which we acquired on August 1, 2024, from its evaluation of the effectiveness of our disclosure controls and procedures. White Oak Senior Living represented 15% of our consolidated total assets and 4% of our consolidated total net operating revenues and grant income as of and for the nine months ended September 30, 2024. We are in the process of integrating White Oak Senior Living into our system of internal control over financial reporting.

Other than with respect to the integration of White Oak Senior Living into our system of internal control over financial reporting, there have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. | Legal Proceedings.

For a discussion of prior, current, and pending litigation of material significance to NHC, please see Note 17 of this Form 10–Q.

Item 1A. | Risk Factors.

During the nine months ended September 30, 2024, there were no material changes to the risk factors that were disclosed in Item 1A of National HealthCare Corporation’s Annual Report on Form 10-K for the year ended December 31, 2023.

Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds.

Not applicable

Item 3. | Defaults Upon Senior Securities.

None

Item 4. | Mine Safety Disclosures.

Not applicable

Item 5. | Other Information.

None

40

Table of Contents

Item 6. | Exhibits.

| (a) | List of exhibits

EXHIBIT INDEX

Exhibit No. |  | Description
3.1.1 |  | Certificate of Incorporation of National HealthCare Corporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s registration statement on Form S-4 (File No. 333-37185) dated October 3, 1997.)
3.1.2 |  | Certificate of Amendment to the Certificate of Incorporation of National HealthCare Corporation (Incorporated by reference to Exhibit 3.5 to the quarterly report on Form 10-Q filed on August 3, 2017.)
3.4 |  | Restated Bylaws as amended February 14, 2013 (Incorporated by reference to Exhibit 3.5 to the quarterly report on Form 10-Q filed on May 8, 2013.)
4.1 |  | Form of Common Stock (Incorporated by reference to Exhibit 4.1 to the quarterly report on Form 10-Q filed on August 3, 2017.)
10.1 |  | Purchase and Sale Agreement dated May 31, 2024 between NHC/OP, L.P., a wholly owned subsidiary of NHC, and Douglas M. Cecil, Oliver K. Cecil, Jr., Dorothy Dean Cecil, Jeni Cecil Feeser, Beth Creech Cecil, John Barber And Teresa J. Cecil, As Trustee Of The Teresa J. Cecil Revocable Trust U/A Dated July 20, 2006, As Amended And Restated On February 15, 2023 (Incorporated by reference to Exhibit 10.1 to the quarterly report on Form 10-Q filed on August 8, 2024.)
31.1 |  | Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2 |  | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32 |  | Certification pursuant to 18 U.S.C. Section 1350 by Chief Executive Officer and Chief Financial Officer
101.INS |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive File (embedded within the Inline XBRL document and include in Exhibit 101)

41

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| NATIONAL HEALTHCARE CORPORATION
| (Registrant) |
Date: November 7, 2024 | /s/ Stephen F. Flatt |
| Stephen F. Flatt |
| Chief Executive Officer |
Date: November 7, 2024 | /s/ Brian F. Kidd |
| Brian F. Kidd |
| Senior Vice President and Chief Financial Officer |

42